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ABSTRACT 
Development and Characterization of Tissue Engineered Blood Vessel Mimics 
Under “Diabetic” Conditions 
Shelby Gabrielle Kunz 
The development of tissue engineered blood vessel mimics for the testing of 
intravascular devices in vitro has been established in the Cal Poly tissue engineering lab. 
Due to the prevalence of cardiovascular disease in diabetic patients and minimal 
accessible studies regarding the interactions between diabetes and intravascular devices 
used to treat vascular disease, there is a need for the development of diabetic models that 
more accurately represents diabetic processes occurring in the blood vessels, primarily 
endothelial dysfunction. This thesis aimed to create a diabetic blood vessel mimic by 
implementing a high glucose environment for culturing human endothelial cells from 
healthy umbilical veins (HUVECs) and from diabetic coronary arteries (DHCAECs). The 
characterization of these BVMs was achieved using immunofluorescence, scanning 
electron microscopy (SEM), and qPCR gene expression analysis. 
 From this study, it was determined that HUVECs and DHCAECs are robust 
enough to be cultured in a high glucose environment – analogous to hyperglycemia – and 
these cells exhibited different characteristics when evaluated under microscopy and 
qPCR gene expression. The immunofluorescence and SEM imaging showed presence of 
cells within each blood vessel mimic. The qPCR gene expression analysis demonstrated 
that mRNA expression of endothelial nitric oxide synthase (eNOS), platelet endothelial 
cell adhesion molecule (PECAM), and receptor for advanced glycation end products 
(RAGE) differs between HUVECs and DHCAECs, as well as between cells cultured in 
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normal and elevated glucose concentrations. These differences in gene regulation indicate 
the potential of the diabetic BVM to more accurately represent the endothelial response 
to diabetes and to the implementation of intravascular devices in the future. It was 
determined that culturing DHCAECs in a high glucose cell media for use in blood vessel 
mimics results in a model that differs considerably from HUVECs grown in normal 
glucose media. It was also determined that there was a difference between DHCAECs 
cultured in high glucose media and normal glucose media, as well as HUVECs cultured 
in high glucose media and normal glucose media. This study aided the development of a 
diabetic BVM; however, there are still improvements to be made, namely the inclusion of 
vascular smooth muscle cells in the model and improving the confluency of the BVM.  
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Chapter 1: Introduction to Diabetes and Tissue Engineered Blood Vessel Mimics 
 
1.1 Diabetes 
According to the Centers for Disease Control and Prevention in 2014, 29.1 million people 
in the United States 20 years or older have diabetes, accounting for approximately 9.3% 
of the total population
 
[1]. Diabetes is considered a major epidemic of this century
 
[2]. 
This disease affects people directly and indirectly, altering their lives significantly from 
the invasiveness of medical treatment to the accompanying financial consequences. In 
2012, it is estimated that diabetes mellitus costs in the United States reached $245 billion, 
which is comprised of direct medical costs, disability, work loss, and premature death
 
[1].  
Diabetes mellitus is a chronic metabolic disease that results in hyperglycemia due 
to insulin insufficiency. The method by which the insulin insufficiency develops indicates 
type 1 versus type 2 diabetes. In type 1 diabetes mellitus there is autoimmune destruction 
of beta-cells of the pancreas that produce insulin, resulting in an insulin deficiency. In 
type 2 diabetes there is reduced insulin production by the beta-cells; however, the 
patients’ cells – primarily of skeletal muscle, liver, and adipose tissue – are insulin 
resistant resulting in hyperglycemia, hyperinsulinemia, and impaired insulin function
 
[3, 
4]. In both type 1 and type 2 diabetes there are significant microvascular and 
macrovascular complications that arise because of the chronic elevation of blood glucose 
levels
 
[4]. These complications, illustrated in table 1, include retinopathy leading to loss 
of vision; nephropathy leading to renal failure; peripheral neuropathy with risk of foot 
ulcers, amputations and Charcot joints; and autonomic neuropathy causing 
gastrointestinal, genitourinary, and cardiovascular symptoms
 
[3]. Diabetic patients are 
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also at a higher risk for developing atherosclerotic cardiovascular, peripheral arterial, and 
cerebrovascular disease
 
[3].  
 
Table 1: Major complications of diabetes, resulting conditions, and associated outcomes 
[3, 4, 5, 6]. 
Microvascular Macrovascular 
Retinopathy Loss of vision Cardiovascular 
disease 
Myocardial 
infarction 
 
Nephropathy Renal Failure Cerebrovascular 
disease 
Stroke 
Peripheral 
Neuropathy 
Foot ulcers, 
amputations, and 
Charcot joints 
 
 
 
 
Other 
Autonomic 
Neuropathy 
Gastrointestinal, and 
genitourinary 
symptoms (sexual 
dysfunction) 
Depression 
Dementia 
 
 
For this thesis, the focus was on the cardiovascular complications of diabetes mellitus and 
the mechanisms that cause these complications. Cardiovascular disease (CVD) is one of 
the most detrimental complications of diabetes, accounting for more than half of the 
mortality of diabetic patients
 
[7].  The term “cardiovascular disease” encompasses 
numerous conditions: coronary artery disease, high blood pressure, myocardial infarction, 
arrhythmia and congestive heart failure, among others. For the diabetic population, it is of 
particular concern for the premature development of atherosclerosis and increased risk of 
myocardial infarction (MI). A diabetic’s risk of MI is equivalent to the risk of a non-
diabetic who has previously suffered an MI
 
[7]. These cardiovascular disorders stem from 
dyslipidemia, poor control of blood glucose, and elevated blood pressure
 
[4]. 
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Furthermore, endothelial dysfunction – primarily linked to chronic hyperglycemia – is an 
underlying cause of atherogenesis and ultimately leads to atherosclerosis
 
[4].  
 
1.1.1 Endothelial Dysfunction in Diabetes Mellitus 
Diabetes mellitus, with correlated insulin resistance, causes numerous endothelial 
dysfunctions that compromise the anti-atherogenic role of the vascular endothelium
 
[8]. 
Hyperglycemia in diabetics contributes to dysfunction of the endothelium by disrupting 
vascular homeostasis via vasoactive factors – such as angiotensin and nitric oxide – 
compromising permeability, adhesiveness, and integrity
 
[4]. This leads to increased 
oxidative stress and inflammation, causing blood vessels to become pathogenic, 
proinflammatory and thrombogenic, leading to premature atherosclerosis and further 
cardiovascular disorders
 
[4]. 
In a healthy patient, the endothelium functions to prevent platelet and leukocyte 
adhesion to maintain the balance of profibrinolytic and prothrombic activity. It is 
hypothesized that this function is disrupted in diabetic patients due to increased oxidative 
stress on endothelial cells and vascular smooth muscle cells
 
[4]. There are several 
hypothesized mechanisms by which chronic hyperglycemia may lead to an increase in 
oxidative stress in endothelial cells, as seen in Figure 1: (1) activation of the polyol 
pathway, (2) increased formation of advanced glycation end-products (AGEs), (3) redox 
potential alterations, and (4) stimulation of the diacylglycerol(DAG)-protein kinase 
C(PKC) pathway
 
[8, 9].  
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Figure 1: Processes initiated by hyperglycemia that contribute to 
endothelial dysfunction
 
[8]. 
The polyol pathway involves the reduction of glucose to sorbitol and the conversion of 
sorbitol to fructose via aldose reductase (AR) and sorbitol dehydrogenase(SDH), 
respectively
 
[10]. AR uses reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) as a co-factor, while SDH uses oxidized nicotinamide adenine dinucleotide 
(NAD+) as a co-factor
 
[10]. The activation of these enzymes results in the formation of 
oxidized NADPH, or NADP, and the reduced form of NAD
+
, or NADH, respectively. 
The byproduct NADH, of the polyol pathway, is oxidized by NADH oxidase (NOx) to 
produce reactive oxygen species (ROS)
 
[10]. Fructose, another byproduct of the polyol 
pathway, is metabolized to fructose-3-phosphate (F-3-P) and 3-deoxyglucosone (3-DG) 
contribute to advance glycation end-product (AGE) formation, which then binds to its 
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receptor to increase oxidative stress
 
[10]. The effects of increased glucose on the polyol 
pathway is shown in Figure 2A. 
Similar to the polyol pathway, glucose oxidation – or the first reaction of glucose 
metabolism shown in Figure 2B – results in the production of NADH [11]. Increased 
glucose oxidation in diabetics results in excess NADH – either through glucose 
metabolism or the polyol pathway – which reacts with the enzyme NADH oxidase to 
produce ROS
 
[10]. Glucose oxidation also leads to an increase in advanced glycation 
end-products (AGEs) due to the non-enzymatic reaction of glucose metabolites and other 
glycation processes.  
 
 
 Figure 2: (A) Effects of increased glucose on the polyol pathway
 
[10]. (B) Glucose 
oxidation reaction resulting in the formation of NADH. 
 
(A) 
(B) 
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Hyperglycemia also activates the diacylglycerol (DAG)-protein kinase C (PKC) pathway. 
Glucose promotes synthesis of DAG, which is crucial in the function of PKC
 
[9]. It is 
commonly held that PKC may have numerous adverse effects on vascular function 
through the activation of NADPH oxidase and endothelial nitric oxide synthase (eNOS)
 
[8]. These enzymes produce superoxide (O2
-
) which contributes further to oxidative stress 
and the production of AGEs in the blood vessels of diabetics
 
[8].  
The increase in ROS and AGE production contributes to the rapid progression of 
atherosclerosis seen in diabetes. AGEs accumulate within vessel walls, inhibiting nitric 
oxide (NO) function on vascular smooth muscle cells (VSMCs), forming collagen cross-
links that alter cell structure and trap plasma proteins, and bind to the receptor for 
advanced glycation end products (RAGE) to alter cell function
 
[8, 12]. RAGE activation 
signals transcription of multiple adhesion molecule proteins, increased intake of oxidized 
low-density lipoproteins (OxLDL) and foam cell formation, as well as NADPH oxidase – 
perpetuating the production of ROS
 
[12, 13]. When interacting with the vessel wall, 
AGEs also initiate the formation of OxLDL, increase vascular permeability, and increase 
endothelial leukocyte adhesion molecule expression; ultimately resulting in the formation 
of atherosclerotic plaques within the vessels through processes listed in Figure 3
 
[8].  
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Figure 3: Progression of endothelial dysfunction into atherosclerosis and 
coronary artery disease
 
[13]. 
For this thesis, the pathophysiology of diabetes and endothelial dysfunction is 
important to replicate aspects of this condition in vitro. Although the disease process of 
diabetes is complex and involves the interaction of numerous cell types, there are some 
responses that are specific to the endothelium that may be able to be replicated in a 
diabetic blood vessel model. Ideally, the diabetic blood vessel model will replicate the 
increase in adhesion molecules, oxidative stress and AGEs – and the respective receptors 
– which are key in the pathogenesis of endothelial dysfunction associated with diabetes. 
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1.1.2 Coronary Artery Disease and Diabetes 
As diabetes progresses, the effects of endothelial dysfunction cause adults with diabetes 
to be at an increased risk for coronary artery disease (CAD), heart attack, stroke and 
angina
 
[14]. The development of CAD with diabetes is due to endothelial dysfunction, 
which enhances the formation of atherosclerotic plaques.  The current standard of care is 
either coronary artery bypass grafting (CABG), or percutaneous coronary intervention 
(PCI)
 
[10]. CABG, which is typically performed as open-heart surgery, requires making a 
large incision through the chest and sternum, and placing the patient on cardiopulmonary 
bypass, to allow the surgeon to reroute blood flow around the blocked vessel using a 
graft. Bypass grafts can be either an autologous vein or artery obtained from a prior 
harvesting surgery, or a synthetic graft constructed from biomaterials. PCI is the use of 
catheters, guided by fluoroscopy, to gain access to the affected coronary artery to place a 
stent that maintains patency of the vessel. This treatment method is often preferred to 
CABG because is it less invasive and capable of treating complex lesions
 
[15].  
 
1.1.3 Efficacy of Coronary Artery Stents 
The treatment of CAD in patients with diabetes has been shown to have worse outcomes 
in terms of mortality, myocardial infarction and need for revascularization than patients 
without diabetes
 
[16]. In one specific study, diabetics had higher mortality after PCI 
compared to CABG, which may be attributed to the medical therapies used to control 
hyperglycemia and other systemic symptoms of diabetes
 
[17]. Another study found that 
diabetic patients, within a population experiencing ST-segment elevation myocardial 
infarction (STEMI), had a worse outcome at 3-year follow-up after PCI, compared to the 
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STEMI population without diabetes
 
[18]. These researchers also found that diabetic 
patients were at a higher risk of stent thrombosis; however, this risk was reduced with the 
advent of everolimus-eluting stents
 
[18]. Everolimus, an immunosuppressant drug, is 
used to prevent restenosis of vessels after PCI treatment of CAD, and may or may not 
interact with the pathological mechanisms of diabetes. These investigations are primarily 
retrospective and observational, such as subgroup analyses within a larger study
 
[16, 18]. 
This means that there is not a wealth of data available for the evaluation of such therapies 
for diabetic patients that would allow for the improvement of treatment and, ultimately, 
patient outcomes. Due to the increased morbidity and mortality of this subgroup of 
patients, there is a growing need for the development of a well-defined model for further 
evaluation of CAD treatment –as well as other medical therapies– in diabetic patients 
[16]. There have been several animal models developed to investigate various aspects of 
the diabetic condition, including streptozotocin-induced diabetic rats and mice, 
spontaneously mutated rats such as Zucker Diabetic Fatty Rats (ZDF), genetically 
modified mice models, diabetic Yucatan miniswine, and streptozotocin-induced diabetic 
domestic pigs [19, 20]. However, rodent models are anatomically very small for testing 
stents or other intravascular devices and all animal models may differ in vascular and 
endothelial cells outcomes due to species-specific responses [21]. Therefore, to obtain a 
better understanding of the effectiveness of intravascular devices such as stents in a 
diabetic environment specific to humans, a tissue engineered blood vessel mimic can be 
used as a simplified model for preclinical in vitro testing.  
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1.2 Tissue Engineered Blood Vessel Mimics 
In recent years, tissue engineering has emerged as a new scientific field that involves the 
fabrication of new and functional living tissue from living cells in combination with a 
matrix or scaffolding to guide development
 
[22]. Within this paradigm of cells and 
scaffold, there are a myriad of options available depending on the tissue being created. 
One application for tissue engineering is the creation of small diameter vascular grafts for 
CABG that might mimic the functional properties of native tissues
 
[23]. Due to the 
complexity and novelty in the creation of tissue engineered vascular grafts (TEVGs), 
there have been significant challenges in clinical application
 
[23]. However, the 
development of TEVGs has led to the employment of these technologies as simple in 
vitro blood vessel models for preclinical testing of intravascular devices, such as stents
 
[24]. In the Cal Poly Tissue Engineering lab, 3-dimensional tissue-engineered blood 
vessel constructs – or blood vessel mimics (BVMs) – are being developed as an in vitro 
preclinical testing environment for intravascular devices
 
[25].  
 
1.2.1 Structure of BVMs 
As in any tissue engineering application, it is the goal of BVMs to mimic certain 
characteristics of native blood vessels. Native vessel anatomy features three layers: tunica 
intima, tunica media, and tunica adventitia as seen in Figure 4A. The tunica intima 
consists of a monolayer of endothelial cells, or endothelium, that directly interacts with 
blood, and functions to prevent thrombosis formation and minimize friction for 
continuous blood flow
 
[26]. The tunica media is composed of smooth muscle cells 
arranged circularly around the circumference of the vessel with sheets of elastin
 
[26]. 
11 
 
Finally, the tunica adventitia is the outermost layer and is composed of loosely woven 
collagen fibers that serve to protect and reinforce the vessel
 
[26]. 
 
 
Figure 4: (A) Anatomical cross-section of artery
 
[27]. (B) Theoretical 
cross-sectional structure of tissue engineered blood vessel mimic.  
 Currently in the Cal Poly lab, an electrospun poly(lactic-co-glycolic-acid) (PLGA) 
scaffold is used because of its similarity to the natural collagen and elastin-filled 
extracellular matrix of blood vessels, as well as its biocompatibility [28]. Primary human 
smooth muscle cells and endothelial cells, expanded through in vitro culture, are 
introduced through the lumen of the BVM to replicate the three layers of native vessels, 
as illustrated in Figure 4B [25].  
 
1.2.2 Fabrication of BVMs 
A previously established method is used to produce a BVM in the tissue engineering lab 
[25]. First, the scaffold is conditioned in a high-protein media within a perfusion 
bioreactor to improve cell adhesion to the synthetic polymer. The bioreactor consists of 
the chamber containing the BVM, an 8-roller peristaltic pump, and a media reservoir as 
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shown in Figure 5. Next, human umbilical artery smooth muscle cells (HUASMCs) are 
pressure sodded into the lumen of the scaffold, followed by human umbilical vein 
endothelial cells(HUVECs), in the bioreactor chamber.  
 
Figure 5: Blood vessel mimic bioreactor set up in 
incubator at 37°C and 5% CO2. 
 
1.3 Development of a Diabetic BVM Model 
Currently, the BVMs produced represent a “healthy” vessel using human umbilical vein 
endothelial cells (HUVECs) and HUASMCs. Other cell sources have been used in BVM 
construction, including human coronary artery endothelial cells (HCAECs) and to a 
limited extent, diabetic human coronary artery endothelial cells (DHCAECs) [29]. The 
initial steps were taken to develop a “diabetic” blood vessel mimic through the 
development of media solutions of various glucose concentrations to replicate a 
hyperglycemic environment with bovine aortic endothelial cells (BAECs) and HUVECs 
[30]. From this study, it was determined that endothelial cells have increased glucose 
consumption when exposed to increased glucose concentrations in the cell media [30]. 
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Although this study provides a foundation for the development of the diabetic blood 
vessel mimic, it did not incorporate the use of DHCAECs and did not include extensive 
characterization of the BVMs. The DHCAEC BVM has not been well-characterized and 
has not been compared to the previously developed healthy BVMs.  
For this thesis, potential parameters for a diabetic BVM were studied by 
comparing the use of HUVECs and DHCAECs in a blood vessel mimic construct, as well 
as the effects of implementing an in vitro hyperglycemic environment for cell culture. 
There were two variables in the BVM protocol that were investigated: (1) cell type and 
(2) concentration of glucose in cell media. Cell media typically contains 5.5mM (1g/L) of 
glucose – approximately normal blood glucose levels in vivo – for normal cell function, 
since glucose is a source of energy
 
[31]. Therefore, the control groups for cell type and 
glucose concentration were HUVECs and normal endothelial cell media (5.5mM 
glucose), respectively. BVMs for this control group have been well-characterized by 
previous students using scanning electron microscopy (SEM), immunofluorescence, and 
histology. Preliminary qPCR analysis has been previously performed on BVMs using 
HUVECs and human umbilical artery smooth muscle cells (HUASMCs), and HCAECs 
and human coronary artery smooth muscle cells (HCASMCs); however, the qPCR work 
was not well-documented and gene expression data is relative to the experimental 
conditions in question
 
[29]. This means that qPCR methods are not well-established and 
previous gene expression data cannot be applied in general to BVM characteristics, 
therefore a brief introduction to these techniques will be provided.  
In addition to qPCR characterization, the control and experimental BVMs were 
also characterized using immunofluorescence, and SEM to verify that the BVMs 
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produced were consistent with previous experiments completed by the Cal Poly Tissue 
Engineering Research Laboratory [25].  
 
1.3.1 Background on Immunofluorescence Analysis of BVMs 
Immunofluorescence is primarily used to detect the presence of specific cellular proteins 
via selective antibodies labeled with fluorophores that can be detected under wide field 
fluorescence, among other imaging and data collecting techniques
 
[32]. This is especially 
useful in determining phenotype of cells and differentiating between cell types, 
depending on the cellular proteins chosen to isolate via fluorophore. For tissue 
engineered blood vessel mimics platelet endothelial cell adhesion molecule (PECAM), 
also known as CD31, was selected to determine the presence of human endothelial cells 
in the blood vessel mimic during analysis.  
PECAM is a cell junction protein present on endothelial cells that plays a role in 
cell-to-cell adhesion and the inflammatory process
 
[33]. In situ, PECAM is expressed on 
continuous endothelium of all blood vessel types and is not expressed on fibroblasts or 
epithelial cells – which are also present in blood vessels [33, 34]. PECAM has been used 
as an immunostaining marker for identifying endothelial cells in a variety of tissue 
engineering applications, including vascular grafts that utilize HUVECs [35, 36, 37, 38]. 
Due to the prevalence of PECAM at endothelial cell junctions and its specificity to 
vascular endothelial cells, it is an ideal marker for immunofluorescent staining of 
HUVECs and DHCAECs in tissue engineered BVMs.  
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1.3.2 Background on qPCR Analysis of BVMs 
Quantitative polymerase chain reaction (qPCR) is a well-established method for 
analyzing gene expression in biological samples. Gene expression refers to the amount of 
mRNA present in a sample
 
[39]. qPCR allows for the analysis of specific genes; however, 
it is not ideal for large quantities of RNA, or samples with complex RNA – such as RNA 
isolated from multiple cell types – as it has relatively low throughput [39]. For this study, 
qPCR analysis may be useful in determining gene expression since the focus is on a 
single cell type for each BVM.  
There are several types of qPCR technologies available to accomplish this 
analysis: endpoint qPCR, real-time qPCR, and reverse-transcription qPCR (RT-qPCR). 
Endpoint qPCR was one of the first PCR systems that allowed for quantification; 
however, there are major limitations because of the need to visualize and quantify PCR 
products after reaction completion through agarose gel electrophoresis
 
[39]. This 
technique is best used for binary analysis to determine the presence of a gene, rather than 
the relative expression of a gene
 
[39]. Real-time qPCR allows for the quantification of 
gene expression throughout the course of the reaction, minimizing experimental error due 
to reaction efficiency and post-processing
 
[39]. This process uses a fluorescent detector 
molecule, such as SYBR green, to obtain a quantitative measurement of PCR product in 
“real time” during each PCR cycle [39]. RT-qPCR is a type of real-time qPCR method 
that optimizes the protocol by combining the final step of sample preparation with real-
time qPCR, minimizing the opportunities for error and contamination. Due to the 
sensitivity and quantitative measurements obtained by real-time qPCR, this method was 
used to obtain gene expression data.  
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1.3.2.1 Genes of Interest 
One of the advantages of qPCR is the ability to determine the expression of a single gene 
within the entire transcriptome of a given sample; however, this means that the genes 
selected must be specific to the cell type and disease process of interest. Given that this 
study is investigating human endothelial cells and diabetes, the genes of interest needed 
to be selected accordingly.  
Platelet Endothelial Cell Adhesion Molecule (PECAM) - As previously 
mentioned, the effects of diabetes on vascular tissue largely revolves around the onset of 
endothelial dysfunction due to hyperglycemia. If endothelial dysfunction continues to 
progress, inflammation of the endothelium occurs and initiates the development of 
atherosclerosis. PECAM plays a role in endothelial cell interactions, and inflammation 
processes, and has shown to be expressed in atherosclerotic lesions in vivo
 
[33, 40]. It has 
been demonstrated that hyperglycemia causes an increase in the expression of adhesion 
molecules, such as endothelial-leukocyte adhesion molecule-1, vascular cell adhesion 
molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1) in HUVECs, and 
inflammation determines the degree of adhesive properties exhibited by human 
endothelial cells
 
[40]. However, in previous studies, it was found that HUVECs cultured 
in high glucose conditions in vitro did not have altered PECAM expression compared to 
HUVECs cultured in normal glucose conditions
 
[41]. This gene was selected to discern 
whether HUVECs and DHCAECs behave differently when cultured in high glucose 
conditions, and is associated with increased oxidative stress and endothelial dysfunction 
due to hyperglycemia, as shown in Figure 6.  
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Figure 6: Progression of processes involved in the development of atherosclerosis from 
hyperglycemia. 
 
Receptor for Advanced Glycation End Products (RAGE) - The production of 
AGEs plays a large role in the development of endothelial dysfunction, as previously 
discussed and shown in Figure 6. The increase in AGE production results in increased 
RAGE activation on endothelial cells, which triggers the transcription factor nuclear 
factor-κB (NFκB) that modifies cell function [12]. This change in the biological 
properties of ECs result in endothelial dysfunction
 
[40]. In studies of vascular 
inflammation in diabetic patients, it was found that the increase in AGEs due to 
hyperglycemia results in the increased expression of RAGE in human aortic endothelial 
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cells
 
[42]. RAGE was chosen as a gene of interest because it is known to increase in 
expression when endothelial cells are exposed to elevated glucose conditions, it is also an 
indicator for the increased production of AGEs, which occurs early in the pathogenesis of 
diabetic endothelial dysfunction [43].  
Endothelial Nitric Oxide Synthase (eNOS or NOSIII) - Endothelial nitric oxide 
synthase (eNOS) is a protein that produces nitric oxide(NO) found in endothelial cells. 
The synthesis of NO typically results in vascular smooth muscle relaxation and 
vasodilation in vivo; however, in diabetes it has been found that NO production is 
decreased in blood vessels
 
[44]. The direct effect of glucose on NO production has not 
been well-studied, however it has been suggested that hyperglycemia may alter the 
function of eNOS, resulting in the production of superoxide (O2
-
) rather than NO
 
[44, 45]. 
It has been found that eNOS gene expression in human aortic endothelial cells is 
increased with prolonged exposure – 5 days – to high glucose [45]. eNOS was chosen as a 
gene of interest because of its possible involvement with the PKC pathway in the 
pathogenesis of diabetic endothelial dysfunction that has not been accounted for with 
PECAM or RAGE.  
 
1.4 Summary and Aims of the Thesis 
1.4.1 Establishing qPCR Methods for BVM Analysis 
Currently, BVMs produced in the lab are characterized using hematoxylin and eosin 
staining, immunofluorescence, and scanning electron microscopy. Although these 
analyses are beneficial for exhibiting cell presence in the BVMs, they are primarily 
image-based and do not account for biological processes occurring at the molecular level. 
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With the development of a diabetic BVM, the implementation of gene expression 
analysis would be beneficial to obtain a better understanding of cellular processes in both 
healthy and diseased cell states, as well as disease processes that may or may not be 
occurring in the diabetic endothelial cells. The first aim of this thesis was to improve 
upon previous attempts to complete gene expression analysis on the tissue engineered 
blood vessel mimics by optimizing and documenting a protocol, and to apply this 
protocol to the study of HUVECs and DHCAECs in BVMs.  
 
1.4.2 Establishing Glucose Concentrations to Model Hyperglycemia 
The Tissue Engineering Lab at Cal Poly has successfully developed and characterized a 
healthy blood vessel mimic using human umbilical vein endothelial cells (HUVECs) and 
human umbilical artery smooth muscle cells (HUASMCs). These BVMs have been used 
for the testing of intravascular medical devices in vitro. In recent work by another 
student, a preliminary “diabetic” BVM was created using diabetic human coronary artery 
endothelial cells (DHCAECs). Although this preliminary diabetic model demonstrated 
the ability to create a BVM using DHCAECs, it did not account for the hyperglycemic 
condition DHCAECs are subjected to in vivo. Therefore, the second aim of this thesis 
was to improve upon the capabilities for creating “diabetic” tissue engineered blood 
vessel mimics by determining an appropriate glucose concentration in cell culture media 
to simulate hyperglycemia, and to distinguish the effects of the simulated hyperglycemic 
environment on HUVECs and DHCAECs. 
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1.4.3 Applying High Glucose Concentrations to Diabetic BVMs 
Once protocols for implementing qPCR and producing an elevated glucose condition for 
cell culture were established, the protocols were applied in conjunction with the 
previously established method for the development of blood vessel mimics. The third, 
and final, aim of this thesis was to apply and analyze the effects of introducing elevated 
glucose conditions to BVMs and the use of DHCAECs to more accurately model the 
hyperglycemic condition of diabetics.  
It is hypothesized that the selected genes of interest: PECAM, RAGE, and eNOS 
will be upregulated, or expression will be increased, in the DHCAECs compared to the 
HUVECs and in the cells cultivated in high glucose conditions compared to the normal 
glucose conditions. The increase in the expression of these genes for DHCAECs 
implemented in a BVM would indicate the potential of the tissue engineered blood vessel 
mimics to exhibit similar characteristics to diabetic endothelium in blood vessels. 
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Chapter 2: Preliminary Study to Establish Methods for qPCR Analysis of HUVECs 
and DHCAECs 
 
2.1 Introduction 
In the tissue engineering lab, there has been previous work to characterize blood vessel 
mimics (BVMs) using quantitative polymerase chain reaction (qPCR) in order to 
understand molecular expression of human umbilical vein endothelial cells (HUVECs) 
and human coronary artery endothelial cells (HCAECs)
 
[29]. However, qPCR analysis 
has not been repeated or implemented as standard analysis in the lab for current BVM 
studies. The previous work also did not include the investigation of a diseased cell state; 
therefore, the genes of interest were not applicable to diabetic cells. The first aim of this 
thesis is to improve upon the previous qPCR protocol and to include DNA primers for 
genes of interest associated with the disease process of diabetic endothelial dysfunction. 
 
2.2 Principles of Real-Time qPCR 
The basic principle of polymerase chain reaction (PCR) is the ability of DNA polymerase 
to synthesize a new strand of DNA complementary to an offered template strand
 
[46]. 
Due to the nature of DNA polymerase, it can only add nucleotides to a preexisting 3’ end 
and requires a primer to initially bind to a target strand of template DNA
 
[46]. The 
necessity of a DNA primer allows for the selection of a specific sequence of nucleotides, 
or a selected gene, to be synthesized by DNA polymerase. To perform qPCR, the 
template DNA, the desired DNA primer, and a fluorescent marker are combined into a 
sample well and placed in a thermocycler equipped with a real-time qPCR system. For 
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this study, SYBR green was used as the fluorescent marker because it is inexpensive and 
is not sequence-specific – allowing for use with any DNA primer. SYBR green is an 
intercalating dye that emits fluorescence when bound to double stranded DNA
 
[39].  
There are three steps to the reaction cycle as shown in Figure 7: (i) denaturation, 
(ii) annealing, and (iii) elongation. First, the samples are heated to 95°C for 20 seconds, 
causing strand separation of the template DNA by disrupting the hydrogen bonds 
between complementary bases, known as the denaturation step
 
[46].  Next, the annealing 
step occurs when the samples are cooled to 60°C for 30 seconds, allowing the DNA 
primers to bond, or anneal, to the single-stranded DNA template. The DNA primers are 
composed of a specific sequence related to the gene of interest, and will only form DNA-
DNA hydrogen bonds if the primer sequence closely matches the template sequence
 
[46]. 
Finally, DNA polymerase is able to bind to the 3’ end of the template DNA-DNA primer 
structure and synthesize a new complementary DNA strand from the template DNA 
strand. DNA polymerase adds nucleotides, also known as deoxynucleotide triphosphates 
(dNTPs), to the DNA primer in the elongation step. This concludes one cycle of PCR. 
During the elongation step, the fluorescent marker SYBR green binds to the formed 
double-stranded DNA and emits fluorescence. The amount of fluorescence is measured at 
the conclusion of each cycle. This process is repeated for 40 cycles, resulting in the 
exponential amplification of DNA. The real-time qPCR instrument plots the measured 
fluorescence against the cycle number, resulting in an amplification plot. The 
fluorescence on the amplification plot represents the accumulation of double-stranded 
DNA product over the duration of the entire PCR reaction. This is quantified as the Ct, or 
cycle threshold, to reach a minimum amount of fluorescence.  
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Figure 7: Operating principle of polymerase chain reaction
 
[47]. 
 
2.3 Methods 
2.3.1 Isolating RNA 
In order to perform qPCR, messenger RNA (mRNA) had to be isolated from the tissue or 
cell samples. This was accomplished by lysing cells to access cell contents. Following the 
diagram in Figure 8, RNA purification was performed by adding a buffer solution and 
70% ethanol to the lysate, and transferred to a spin column
 
[48]. Spin columns use forces 
generated via centrifugation to filter lysate through a silica gel membrane coating
 
[48]. 
The nucleic acid binds to the silica gel, while the other cell components continue to pass 
through. This process was repeated to remove membrane lipids, proteins, and other 
cellular contaminants and is referred to as “washing” steps. Finally, nuclease-free water 
was added to remove the nucleic acids from the membrane and the elution was collected 
for use in reverse transcription. The RNeasy Mini Kit (QIAGEN, Hilden, Germany) was 
used in this study, with the detailed protocol for RNA isolation provided in Appendix B.  
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Figure 8: RNA purification using spin column methods. Source: 
www.thermofisher.com. 
The isolated mRNA was then assessed for quantity and purity using concentration and 
ratio of absorbance at 260nm and 280nm (A260/280) values obtained from a 1µL sample 
of isolated RNA and the NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA). The A260/280 value was used to assess the purity of RNA, 
where a ratio of 1.8 to 2.0 generally indicates good quality RNA that is devoid of protein 
contamination
 
[49]. The concentration values of mRNA in each elution was used to 
calculate the available amount of RNA (ng) for cDNA reverse transcription. The 
minimum amount of RNA needed to perform cDNA synthesis is 200ng, which was the 
amount used for the preliminary study. A detailed protocol for RNA quality assessment is 
provided in appendix C.  
 
2.3.2 cDNA Synthesis 
From the mRNA obtained from the biologic samples, reverse transcription was used to 
produce complementary DNA (cDNA). The volume of RNA isolate needed was 
calculated using equation 2.1. Reverse transcriptase and a short RNA-specific primer – 
among other reagents – are combined with the isolated mRNA to produce cDNA. This 
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cDNA was then used as the template DNA in qPCR analysis. The detailed protocol for 
transcription is provided in Appendix D.  
 
(200ng RNA) ∗ (
1mL
[RNA]
ng
nL⁄
) = Volume RNA (μL) (2.1) 
 
2.3.3 Reference Gene Selection 
To complete the data analysis of the Ct values obtained from qPCR, a reference gene 
must be used as an internal reaction control for normalization and calculation of relative 
abundance of each gene of interest [50, 51]. A reliable reference gene must meet several 
criteria: most importantly, it must be expressed at the same level under all experimental 
factors; it should show minimal variability in expression between cell types and 
physiological states of the tissue; and it should demonstrate variability resulting from 
imperfections of the technology and preparation methods [50, 51]. The basic metabolism 
genes or HKGs, by definition, are involved in processes essential for the survival of cells, 
and therefore must be expressed in a stable and non-regulated constant level [52]. It is 
widely-held that the basic metabolism genes – also known as housekeeping genes 
(HKGs) – fulfill these conditions best; however; this is not always true depending on the 
experiment. Many housekeeping genes are not only present in basic metabolic processes, 
but in other functions depending on the gene and tissue type [51]. For each tissue or cell 
type and specific experimental designs, a proper search and validation of reference gene 
is needed to ensure that there is no significant change in expression and to ensure 
accurate data analysis [53].  
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Expression of reference genes must be unaffected by differences in cell type or 
experimental treatment. In this experiment, HUVECs and DHCAECs were treated with 
elevated levels of glucose. A previous study has shown that glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and β-actin (BACT) both display stable expression in HUVECs 
cultured in a hyperglycemia model
 
[54]. In the same study that found RAGE expression 
increases in endothelial cells exposed to hyperglycemic conditions, GAPDH was used as 
a reference gene for their RT-qPCR analysis, with BACT used as an internal control in the 
event GAPDH was not sufficient as a reference gene
 
[42]. GAPDH was also used as a 
reference gene in the study that found elevated eNOS expression in HAECs when 
exposed to high glucose conditions
 
[45]. Both BACT and GAPDH were included in the 
primer verification experiment to determine the optimal reference gene for the remainder 
of the study. 
 
2.3.4 Primer Design 
For each gene of interest, a different DNA primer is needed to run qPCR. Each gene of 
interest requires a set of two DNA primers: a forward and a reverse, for 5’ to 3’ synthesis 
on complementary strands of cDNA. There are validated primer sets for a myriad of 
species-specific genes, thus researchers may select their own primer sets for each gene 
relatively quickly using these available primer sets. In SYBR green-based qPCR, 
specificity of each primer is extremely important as SYBR green will fluoresce when 
bound to any double stranded DNA (dsDNA), regardless if the product is the desired 
gene, or amplicon
 
[39]. Poor primer choice could result in increased fluorescence, 
therefore inaccurate quantification, from nonspecific binding of SYBR green to incorrect 
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amplification products or primer dimer formation. Primer dimer formation occurs when 
the forward and reverse primers bind to each other rather than the template DNA. Proper 
primer selection leads to increased sensitivity of quantification and assay reproducibility. 
With SYBR green, the amplicon length is also important because the longer the product, 
the more dsDNA, which leads to increased fluorescence, which may affect comparison 
studies. The ideal primers for SYBR Green qPCR are highly specific, do not produce 
primer dimers, and have similar amplicon lengths (80-150 bp), which can be achieved 
through quality primer design
 
[55]. One way to ensure specificity is to find primers 18-24 
base pairs (bp) in length
 
[55].  
For this thesis, primer selection played an important role in the development of 
the qPCR protocol used. First, a gene sequence was identified for each gene of interest 
using the GenBank, the National Institutes of Health (NIH) genetic sequence database. 
Once a gene sequence was found that was specific to the gene of interest, mRNA, 
species, and base pair length, the sequence was cross-referenced using PrimerQuest 
provided by Integrated DNA Technologies. PrimerQuest output provided pre-validated 
DNA primers based on the gene sequence, type of qPCR, primer size (length), and 
amplicon size (length). Once a primer set is determined, the primer sequences were input 
in Primer-BLAST, an extension of the GenBank database provided by the NIH. This 
database provides the homology of primer sets. Homology is the existence of similar 
genes that share a primer. For optimal primers, high homology with different variants of 
the same gene and low homology with non-target genes is desired. Appendix G provides 
a detailed protocol for primer design. Two or three primer sets were selected for each 
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gene of interest and the reference genes. A table of all primer sets included in the 
verification is shown in appendix H.  
 
2.3.5 Primer Verification 
To verify the efficiency of the selected primers, a qPCR plate was run with a sample of 
cDNA isolated from HUVECs grown in static culture in normal media. Technical 
triplicates were run for each primer set, as well as a non-template control (NTC) as 
shown in the 96-well plate template in Figure 9. Non-template controls do not contain 
any cDNA and can be used to check for primer contamination and primer dimer 
formation.  
 
 
Figure 9: 96-well plate template, with each color representing different 
primer, for primer verification. 
 
 
2.3.6 qPCR Data Analysis 
The raw data obtained from qPCR is the crossing threshold, Ct, or the number of cycles 
that it takes the reaction to reach a minimum amount of fluorescence. This requires some 
calculation and interpretation to ascertain the quantification of each gene. This analysis 
Technical 
Replicates 
Non-
Template 
Control 
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can determine absolute or relative levels. Absolute quantification involves the calculation 
of number of copies of a specific RNA per sample for a given gene of interest (GOI)
 
[39]. 
Relative quantification determines the level of gene expression for one sample compared 
to another sample, which is more widely used and is used for this thesis. The 2
-ΔΔCt
 
method is the most commonly used to determine relative quantitation
 
[39].   
The 2
-ΔΔCt
 method operates under the assumption that PCR efficiency is 100%, 
such that the PCR product doubles after every cycle
 
[39].  This method also requires the 
use of a reference gene that have a stable expression level in all tissues or cells 
undergoing investigation
 
[54]. Ideally, this reference gene is not regulated or affected by 
experimental conditions. In this analysis, the reference gene is used to normalize the data 
for each sample by determining the ΔCt value as shown in equation 2.2.  
referencesampleGOIsample CtCtCt ,,    (2.2) 
From the ΔCt value, the ΔΔCt value and relative abundance are calculated using 
equations 2.3 and 2.4, respectively.  
controlerimental CtCtCt  exp   (2.3) 
CtAbundance  2    (2.4) 
Then the ΔΔCt value is used to determine the fold change using equation 2.5. 
Fold Change = 2
-ΔΔCt
   (2.5) 
The fold change value represents the level of the gene of interest in the experimental 
sample as a percentage of the level of the gene of interest in the control sample
 
[39]. For 
instance, a value of 1.5 indicates the gene of interest is expressed 150% more in the 
experimental sample compared to the control sample. This method effectively produces a 
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linear relationship for standard statistical tests, such as Student’s t-test or analysis of 
variance (ANOVA), from the exponential Ct values
 
[39].  
In this thesis, the abundance calculation was used to determine the level of gene 
expression because the loss of the control data point in the fold change calculation is 
undesirable. By using abundance, the Ct values are still transformed into data with a 
linear relationship for comparative statistics. Abundance can be interpreted as the 
percentage of expression for the gene of interest relative to the reference gene. A detailed 
protocol of qPCR data analysis is provided in appendix F. 
 
2.4 Results: qPCR Primer Verification  
In order to choose the best primer for each gene, the amplification and melting curves can 
be used to determine the quality of each primer set. An amplification plot is the derivative 
of measured fluorescence as a function of cycle number, while the melting – or 
dissociation – curve is the derivative of measured fluorescence as a function of 
temperature as the thermocycler heats through the dissociation temperature of the 
amplicon
 
[56]. Fluorescence signals occur as a result of SYBR green binding to dsDNA, 
therefore fluorescence is directly proportional to the amount of dsDNA in each sample.  
The amplification curve is used to determine the efficiency of PCR, as well as the 
threshold for which Ct values are obtained for each sample
 
[39]. For primer verification, 
the only variable between each well was the primer set therefore the information obtained 
from the amplification curve is most likely due to primer efficiency. An ideal 
amplification curve shows the reaction going through exponential and linear phases until 
PCR reagents become exhausted, at which point the reaction reaches a plateau, as seen in 
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Figure 10. Assuming there are exactly equal amounts of cDNA and other reagents in 
each well, it would also be expected that exponential amplification of each sample would 
occur around the same cycle number, or have similar Ct values. The NTC was used to 
verify primer dimer formation, which would be visualized as amplification in the NTC 
well. From the first primer set chosen for GAPDH, there was amplification of the NTC at 
curve 1 in Figure 10A. From the third primer set chosen for GAPDH, the amplification 
curve revealed primer efficiency with similar Ct values for both samples, seen at the 
curves crossing the threshold at approximately the same cycle in Figure 10B at curve 2. 
There was also no amplification of the NTC, seen by the lack of a curve at 3 in Figure 
10B.  
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Figure 10: Amplification curves from primer verification for two different primer sets for 
GAPDH. 
 
Since SYBR green non-specifically binds to dsDNA, primer dimer formation and other 
artifacts can lead to error in the amplification curves. To ensure that the desired product 
was amplified, a dissociation cycle is performed after amplification cycles are completed
 
[39]. The dissociation cycle increases the temperature incrementally while fluorescence is 
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measured. As temperature increases, DNA denatures into single strands and fluorescence 
decreases. Dissociation temperature correlates with the length of the amplification 
product, as dissociation temperature increases with product length. Primer dimer 
formation can be identified by significantly lower dissociation temperatures – due to their 
shorter length (18-22bp) – than the desired products (>200bp). In studies of qPCR 
accuracy, it has been found that the analysis of melting curves can distinguish desired 
products from undesired products, eliminating the need for agarose gel electrophoresis of 
qPCR products
 
[56].  
The dissociation curves in Figure 11 correspond with the primer sets used for 
Figure 10. Figure 11A shows primer dimer formation by dissociation curve 1. The 
amplicon of this primer set was also non-ideal as the dissociation curves for two samples 
did dissociate at the same temperature, seen by the curves at 2. Figure 11B shows that 
the NTC did not have any products or primer dimer formation, seen by the flat line at 3. 
The amplicons in the sample wells have close dissociation temperatures as seen at 4. 
The amplification curve also showed that all sample wells had reasonable Ct 
values for the genes of interest. More specifically, the Ct values for the same primer – 
which is specific to each gene of interest – were relatively similar, indicating appropriate 
amplification efficiency.  
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Figure 11: Dissociation curves from primer verification for two different primer sets of 
GAPDH. 
From the analysis of the amplification and dissociation curve for each primer set, a single 
primer set for each gene of interest and reference gene was selected for use in the 
remainder of this study. The dissociation curves were scrutinized especially for primer 
dimer formation as the primer denaturation temperature was provided by the 
manufacturer for each primer. The selected primer sets and sequences for each gene are 
given in Table 2.  
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Table 2: Primer sets and sequences for each gene of interest and reference genes. 
Primer ID Direction Sequence (5’ to 3’) Length 
(bp) 
Homologs 
GAPDH 
(NM_001289745.1) 
Forward GTCGGAGTCAACGGATTTG 19 Self: 3 
Reverse TCCATTGATGACAAGCTTCC 20 Other: 0 
PECAM 
(NM_000442.4) 
Forward CCAGCCCAGGATTTCTTATG 20 Self: 7 
Reverse TCTGCAACACACTGGTATTC 20 Other: 0 
RAGE 
(NM_001136.4) 
Forward AGCGTGCAGAACTGAATC 18 Self: 8 
Reverse GGCTCTGGTTGTAGAAGAAA 20 Other: 1 
eNOS 
(NM_000603.4) 
Forward GTCCTGTGTATGGATGAGTATG 22 Self: 2 
Reverse GCTGTTGAAGCGGATCTT 18 Other: 0 
*BACT was excluded after GAPDH was selected as the reference gene from the pilot    study. 
  
2.5 Conclusion 
This preliminary study was used to show that qPCR analysis of the selected genes of 
interest and reference gene is feasible. The qPCR data showed reasonable amplification 
and dissociation curves, with minimal primer-dimer formation for each primer selected.  
The verification study also showed the formation of a single PCR product, or amplicon, 
for each gene of interest. It was also found that GAPDH was the optimal reference gene 
over BACT. The qPCR data indicated successful completion of the first aim of this thesis, 
to establish a qPCR protocol for the analysis of HUVECs and DHCAECs.  
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Chapter 3: Preliminary Study to Develop a Hyperglycemic Condition In Vitro 
 
3.1 Introduction 
In order to investigate the effect of a simulated hyperglycemic environment on HUVECs 
and DHCAECs in tissue engineered BVMS, a protocol had to be developed for 
replicating a hyperglycemic condition in vitro. A preliminary study was conducted to 
determine the optimal concentration of glucose to add to cell culture to elicit cellular 
responses, without causing apoptosis. For time and cost efficiency, this initial study was 
conducted using HUVECs and DHCAECs grown in flasks and not in a BVM construct. 
The primary outcome of this study was to determine a single glucose concentration to use 
for the creation of “diabetic” BVMs, and to demonstrate the feasibility of creating a more 
accurate diabetic blood vessel model.  
Numerous studies have shown that HUVECs subjected to high glucose 
concentrations in culture may undergo increased apoptosis, or other alterations in cellular 
processes, through various mechanisms associated with diabetes
 
[54, 55, 57]. Previous 
studies used the same control – a normal glucose concentration of 5mM – in cell media; 
however, all studies used different concentrations to represent their high glucose 
condition. These studies also differed in the duration of exposure to the high glucose 
culture conditions, as shown in table 3. From this information, it was determined that two 
levels of high glucose concentrations would be used in the preliminary study to determine 
the extent of apoptosis in HUVECs and DHCAECs. Cell culture media used for the 
culture of endothelial cells typically contain 5.5mM of glucose, which approximates 
normal blood sugar levels in vivo
 
[31, 58, 59]. The second glucose concentration 
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investigated was 10.5mM of glucose as a moderate level, that reflects pre-diabetic blood 
glucose levels, and represents a glycemic threshold when diabetic complications arise in 
vivo
 
[31]. From the studies given and expected time points for a BVM set up in future 
studies, a concentration of 25.5mM of glucose was selected as the high glucose level. 
 
Table 3: Glucose conditions, time, study
 
[37, 42, 43, 45]. 
Study High Glucose 
Concentration 
Duration of 
Exposure 
Outcome 
Bakhashab S, et al. – 
Reference Genes… 
16.5mM 1 day 
n/a 
Cosentino F, et al. – High 
glucose increases nitric oxide 
synthase… 
22.2mM 5 days 
Increased eNOS gene 
expression 
Piconi L, et al. – Constant and 
intermittent high glucose… 20mM Up to 14 days 
Increased apoptosis 
due to ROS 
overproduction 
Ho FM, et al. – High-glucose 
induced apoptosis… 
33mM Up to 2 days 
Cell survival ≤ 24h 
Apoptosis ~48 hours 
 
3.2 Materials and Methods 
Human umbilical vein endothelial cells (HUVECs) and type II diabetic human coronary 
artery endothelial cells (DHCAECs) (Lonza, Basel, Switzerland) were cultured under 
standard conditions (37°C, 5% CO2) in endothelial growth media (Lonza EGM-2, 
cc3162) and coronary endothelial cell media (Lonza EGM-2 MV, cc3202), respectively. 
Endothelial cells were trypsinized and passed from a T75 cell culture flask at 
approximately 90% confluency at a ratio of 1:3 to allow for growth. Cell media was 
replaced every 2 days. This process was repeated until four T75 flasks were obtained for 
each cell type. After 24 hours –to allow for adhesion of cells to the flask – normal cell 
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media was replaced with the experimental treatments as shown in table 4. The remaining 
flasks of cells were frozen down for future use.  
Table 4: Treatment groups to determine glucose concentration. 
 Cell Type 
G
lu
co
se
 C
o
n
d
it
io
n
 HUVECs + Control Media DHCAECs + Control Media 
HUVECs + Moderate 
Glucose 
DHCAECs + Moderate 
Glucose 
HUVECs + High Glucose DHCAECs + High Glucose 
  
3.2.1 Media Preparation 
For this preliminary study, a 0.08M glucose (Sigma Aldrich, St. Louis, MO) solution was 
prepared and autoclaved. Using equations 2.2 and 2.3, the appropriate amount of glucose 
solution, shown in table 5, was added to cell media to obtain the desired treatment 
groups. 
𝐶𝑔𝑙𝑢𝑐𝑜𝑠𝑒𝑉𝑔𝑙𝑢𝑐𝑜𝑠𝑒 = 𝐶𝑑𝑒𝑠𝑖𝑟𝑒𝑑(𝑉𝑚𝑒𝑑𝑖𝑎 + 𝑉𝑔𝑙𝑢𝑐𝑜𝑠𝑒) (2.2) 
 
(𝐶𝑔𝑙𝑢𝑐𝑜𝑠𝑒𝑉𝑔𝑙𝑢𝑐𝑜𝑠𝑒+𝐶𝑚𝑒𝑑𝑖𝑎𝑉𝑚𝑒𝑑𝑖𝑎)
𝑉𝑔𝑙𝑢𝑐𝑜𝑠𝑒+𝑉𝑚𝑒𝑑𝑖𝑎
= 𝐶𝑑𝑒𝑠𝑖𝑟𝑒𝑑 (2.3) 
 
Table 5: Media preparation specifications. 
Final Glucose 
Concentration of 
Media (mmol·L
-1
) 
Volume 
Glucose 
Solution 
(mL) 
Volume of 
Cell Media 
(mL) 
Total 
Volume 
(mL) 
10.5 
 
18.0 250 268.0 
25.5 
 
91.7 250 341.7 
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3.2.2 Immunofluorescence 
After 7 days of cultivation in the specified glucose environment, cells from each flask 
were trypsinized to remove them from each flask, transferred to a 50mL conical, and 
centrifuged to form a cell pellet. The pellet was resuspended in the appropriate glucose 
media and seeded at approximately 1.2 x 10
6
 cells/3mL per well, with duplicate wells for 
each treatment according the Figure 12.  
 
 
Figure 12: Sample and treatment scheme for immunofluorescence analysis. 
Cells were cultivated in the wells for 24 hours, then fixed using 10% formalin buffered 
fixative (Azer Scientific, Morgantown, PA) applied in wells. Each well was gently 
washed with 1mL of phosphate-buffered saline (PBS) (Thermo Fisher Scientific, 
Waltham, MA) to remove any remaining media or fixative. Then a 1% w/w solution of 
saponin in PBS was applied to each well to permeabilize the cell membranes. The 
saponin solution was aspirated and the wells are washed again in PBS. To prevent non-
specific binding of antibodies, the samples were blocked using fetal bovine serum (FBS) 
prior to the application of the PECAM primary antibody. The samples with the primary 
antibody were incubated 8-10 hours before being washed in PBS and the application of 
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the secondary antibody, α-mouse anti-CD31 (PECAM). The secondary antibody was 
incubated at room temperature for 60 minutes before another washing. Finally, a 1:400 
solution of bisbenzimide (BBI) in PBS was applied for 5 minutes and a final wash of PBS 
was completed. All liquids were removed, and each sample was imaged using the 
specifications in table 6 at 10X objective magnification on the widefield fluorescent 
microscope.  
Table 6: Settings used to obtain immunofluorescence images. 
Stain Excitation 
Filter (nm) 
Emission 
Filter (nm) 
BBI 350/50 457/50 
PECAM 490/20 528/38 
 
3.2.3 Gene Expression 
From the same samples used for immunofluorescence, the remaining cells suspended in 
media were centrifuged into a cell pellet, the remaining media was aspirated, and the 
pellet was frozen in liquid nitrogen for qPCR analysis. Total RNA was extracted from 
each sample using the RNeasy Mini Kit (QIAGEN, Hilden, Germany) according to the 
manufacturer’s instructions. The isolated RNA was assessed for quality and quantity 
using a NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA) to obtain concentration, and A260/280 values for each sample. Spectrophotometer 
readings were repeated three times for each sample of isolated RNA to minimize error 
that may arise from non-homogeneity of RNA concentration in the isolated elution. From 
the three readings, average RNA concentration values were determined and used to 
calculate volume needed for reverse transcription of RNA. For reverse transcription of 
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RNA, 200 ng of RNA is required for each sample therefore the volume of isolated RNA 
needed of each sample was calculated using the average RNA concentration and equation 
2.1. Concentration, A260/280 and RNA volume values for each sample are provided in 
appendix I.  
(200𝑛𝑔 𝑅𝑁𝐴) ∗ (
1𝑚𝐿
[𝑅𝑁𝐴]
𝑛𝑔
𝑛𝐿⁄
) = 𝑉𝑜𝑙𝑢𝑚𝑒 𝑅𝑁𝐴 (𝜇𝐿) (2.1) 
 
Complementary DNA was synthesized from the RNA samples using the iScript cDNA 
Synthesis Kit (Bio-Rad, Hercules, CA) according to manufacturer’s instructions to obtain 
a total volume of 20uL of cDNA. This cDNA solution was diluted 1:5 in nuclease-free 
water to obtain a total of 100uL of cDNA solution.  
DNA primers (Integrated DNA Technologies, Coralville, IA) were diluted with 
nuclease-free water from stock solutions of 100µM to working solutions of 15µM. A 
MicroAmp® fast optical 96-well reaction plate (Applied Biosystems, Foster City, CA) 
was prepared with technical triplicates for each treatment group and a non-template 
control (NTC), as shown in Figure 13, and full plate schemes given in table J. Each well 
contained 3.2µL of cDNA, or nuclease-free water for NTCs, 5µL Fast SYBR Green 
Master Mix (Life Technologies, Carlsbad, CA), 2µL forward primer, 2µL reverse primer, 
and 7.8µL of nuclease-free water for a total well volume of 20.0µL.  
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Figure 13: Example of 96-well template used to load samples, where 
each row represents a different sample group apart from row H: non-
template controls. 
Real-time qPCR was performed using 7500 Real-Time PCR Systems (Applied 
Biosystems, Foster City, CA) under the conditions given in table 7 for thermal cycling. 
As previously explained, during thermal cycling the polymerase chain reaction occurs: 
denaturation, annealing, and elongation of DNA – resulting in amplification of the 
desired genes and a measurement of fluorescence after each cycle. 
 
Table 7: Thermocycling settings for 7500 Real-Time PCR System, cycled 40 times. 
Temperature Duration 
95.0 20 secs 
95.0 3 secs 
60.0 30 secs 
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3.2.4 Statistical Analysis 
Mean expression values of each technical triplicate were calculated using the 2
-ΔCt
 
method described in chapter 1, using GAPDH as the reference gene in equations 1.1 and 
1.2 to obtain mean relative abundance. Abundance is presented as mean ± SEM. The 
comparison of gene expression levels between treatment groups was performed using 
two-sample t-tests with Minitab Statistical Software. 
 
3.3 Results 
3.3.1 Observations of Culture 
During the expansion of HUVECs and DHCAECs, it was found that the DHCAECs were 
consistently less confluent than the HUVECs over the same time period. Once the 
glucose treatments were implemented, it was also noted that as glucose concentration 
increased confluency decreased across both cell types. As the normal media groups 
appeared approximately 95-100% confluent at the time point investigated, the 10.5mM 
glucose media groups appeared 85-90% confluent, and the 25.5mM glucose media 
groups appeared approximately 80-90% confluent.  
 
3.3.2 Immunofluorescence 
A representative image for each stain is presented for each treatment group with a third 
composite image that shows the images for each stain overlaid using ImageJ Software. 
Comparing HUVEC immunofluorescence images in Figure 14 and DHCAEC images in 
Figure 15, HUVECs appeared to have higher confluency given the number of 
distinguishable nuclei in the BBI images. For the DHCAEC images, it appears that the 
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confluency decreased from the control media treatment (Figure 15A) to the 10.5mM 
glucose media treatment (Figure 15D) and from the control media treatment to the 
25.5mM glucose media treatment (Figure 15G). It is difficult to discern differences in 
PECAM presence, as it is relative to the number of cells present in the given image; 
however, all samples stained positive for PECAM. 
 
Figure 14: Immunofluorescence staining of HUVECs at 10x objective magnification. 
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Figure 15: Immunofluorescence staining of DHCAECs at 10x objective magnification. 
 
3.3.3 Gene Expression 
The data obtained from qPCR was first inspected using amplification and dissociation 
curves for each gene as quality control. This was to ensure that the assumption of 100% 
PCR efficiency required to perform 2
-ΔCt
 analysis, as mentioned in chapter 1, is met for 
each sample. The dissociation curve was used to determine the presence of primer dimer 
formation, contamination, or multiple qPCR products. If a well did not meet quality 
control standards, the data point was removed from analysis.  
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GAPDH - From the amplification and dissociation curves shown in Figures 16 and 17, 
respectively, it was found that all wells met quality control standards. The dissociation 
curve showed one sample that appeared to have some primer dimer formation, by the 
curve that peaked at a lower temperature comparatively; however, this well was 
identified as the NTC. There was no other primer dimer formation in the experimental 
samples, as seen by the lack of fluorescence signaling in any other sample. This primer 
dimer formation in the NTC also explains the amplification curve that appeared much 
later than the rest of the samples. The amplification curve showed acceptable efficiency 
and the dissociation shows a single amplicon in all sample wells. 
 
 
Figure 16: Amplification curve for GAPDH from 7500 Real-Time 
qPCR System. 
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Figure 17: Dissociation curve for GAPDH from 7500 Real-Time qPCR System. 
PECAM - The amplification curve for PECAM in Figure 18 showed acceptable PCR 
efficiency in all wells, with the appropriate absence of amplification in the NTC well. 
The dissociation curve in Figure 19 revealed a non-desired product was amplified in a 
well corresponding to a sample from HUVECs grown in 10.5mM of glucose, and was 
removed from analysis. In all other wells, the dissociation curve showed one product, no 
primer dimer formation, and an appropriate lack of product in the NTC.  
 
Figure 18: Amplification curve for PECAM from 7500 Real-Time qPCR System. 
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Figure 19: Dissociation curve for PECAM from 7500 Real-Time qPCR System. 
 
RAGE - From the amplification curve in Figure 20, it was found that a well 
corresponding with a HUVEC sample treated with 10.5mM glucose and a well 
corresponding with a HUVEC sample treated with 25.5mM glucose had inadequate 
amplification. These same wells also showed a non-desired product formed in the 
dissociation curve in Figure 21, and these data points were removed from further 
analysis. Otherwise, there was adequate amplification efficiency and amplification of a 
single, desired product without primer dimer formation for the remaining samples and 
single. The NTC showed an appropriate lack of amplification and corresponding lack of 
PCR product. 
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Figure 20: Amplification curve for RAGE from 7500 Real-Time qPCR System. 
 
 
Figure 21: Dissociation curve for RAGE from 7500 Real-Time qPCR System. 
eNOS - All sample wells displayed adequate PCR efficiency on the amplification curve in 
Figure 22, as well as the formation of a single PCR product and lack of primer dimer 
formation on the dissociation curve in Figure 23.  
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Figure 22: Amplification curve for eNOS from 7500 Real-Time qPCR System. 
 
 
Figure 23: Dissociation curve for eNOS from 7500 Real-Time qPCR System. 
 
The relative mean abundance ± standard mean error is presented with significant 
differences determined using two-sample t-tests with unequal variance for each treatment 
group. In order to draw conclusions between glucose treatments as well as cell types, the 
data is presented for each gene with comparisons between glucose treatments within the 
same cell type and between two cell types with the same glucose treatment. 
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3.3.3.1 Comparisons Between Glucose Concentrations 
PECAM - The gene expression analysis of PECAM revealed no significant differences 
between the glucose concentration treatment groups within each cell type in Figure 24; 
however, there is a trend that PECAM expression appears to increase in the groups 
treated with the high glucose concentration compared to the groups did not receive any 
supplemental glucose within each cell type.  
 
 
Figure 24: Results of average relative abundance of PECAM in mRNA isolated from 
HUVECs (A) and DHCAECs (B). 
 
RAGE - The gene expression analysis of RAGE revealed no significant differences 
between glucose concentration treatment within each cell type in Figure 25; however, it 
revealed that the expression of RAGE trended upward with increased glucose 
concentration in the cell media within each cell type. 
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Figure 25: Results of average relative abundance of RAGE in mRNA isolated from 
HUVECs (A) and DHCAECs (B). 
eNOS - Gene expression analysis of eNOS revealed a significant difference between the 
HUVECs cultured in control media and 10.5mM glucose media. This difference displays 
a marked increase in eNOS expression with increased glucose concentration. A similar 
trend is seen in the DHCAECs, but it was not found to be significant. HUVECs appeared 
to have an overall increase in eNOS expression with increases in glucose concentration 
without significance between groups. eNOS expression did not have any noticeable trend 
with respect to glucose concentration in DHCAECs.  
 
 
Figure 26: Results of average relative abundance of eNOS in mRNA isolated from 
HUVECs (A) and DHCAECs (B). 
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3.3.3.2 Comparisons Between Cell Type 
PECAM - The gene expression analysis for PECAM showed a significant difference in 
mean abundance between HUVECs and DHCAECs grown in normal cell media in 
Figure 27A. PECAM expression differs greatly between the two cell types when grown 
in 25.5mM glucose; however, there was no noticeable difference in PECAM expression 
between the two cell types when grown in 10.5mM glucose media.  
 
 
Figure 27: Results of relative abundance of PECAM in mRNA for normal glucose (A), 
moderate glucose (B), and high glucose (C) concentrations. 
 
RAGE - The gene expression analysis for RAGE did not reveal any significant differences 
based on cell type; however, there was a noticeable trend. There was a trend of the 
HUVECs to express increased RAGE compared to the DHCAECs cultured in each 
respective glucose condition seen in Figure 28.  
A B C 
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Figure 28: Results of relative abundance of RAGE in mRNA for normal glucose (A), 
moderate glucose (B), and high glucose (C) concentrations. 
eNOS - The gene expression comparison for cell type returned a significant difference 
between HUVECs and DHCAECs cultured in normal media as seen in Figure 29A. 
There were no noticeable trends associated with cell type comparison for the groups that 
were treated with supplemental glucose as seen in Figure 29B, C.  
 
 
Figure 29: Results of relative abundance of eNOS in mRNA for normal glucose (A), 
moderate glucose (B), and high glucose (C) concentrations. 
 
3.3.3.3 Reference Gene Selection 
To determine if GAPDH was the appropriate reference gene for these samples, the Ct 
values for GAPDH were transformed to linear related data using 2
-Ct
. Then, these values 
A B C 
A B C 
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were used in an analysis of variance (ANOVA) of GAPDH presence in each cell type-
treatment combination. The data met the assumptions needed for ANOVA: the data was 
approximately normally distributed, the data point measurements were independent of 
one another, and had approximately equal variance. It was found that the variance of each 
treatment group was not significantly different from one another.  
 
3.4 Discussion 
The immunofluorescence images obtained from this preliminary study did not reveal as 
much information as anticipated. Due to the subjectivity of determining PECAM 
expression from the immunofluorescence images, the analysis was largely qualitative. 
The BBI images suggested that confluency decreased as glucose concentration increased 
for DHCAECs (Figure 15A, D, G), which may indicate apoptosis of cells in culture. 
From the PECAM images alone, it appeared that all samples had some PECAM-positive 
staining, demonstrating that the cells present are most likely endothelial cells. 
Unfortunately, a live-dead stain was not performed on the samples for this study, which 
would have allowed for the determination of apoptotic activity in endothelial cells grown 
in an in vitro hyperglycemic environment.  
From the gene expression analysis, there were few significant differences in 
expression of any of the genes of interest due to the addition of glucose to the cell media; 
however, there were several noticeable trends relative to glucose concentration in the 
media. One possible reason for the lack of significance in statistical analysis is the 
relatively large standard error values. Standard error accounts for variability relative the 
sample size. In this study, the largest source of error in gene expression can be attributed 
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to pipetting error when adding samples and reagents to plate for PCR. Another possible 
source of error is the small sample size (n= 2 or 3) for all samples.  
With the trends seen in the relative quantities of each gene, the moderate glucose 
concentration (10.5mM) treatment groups were largely inconsistent. For PECAM, there 
appeared to be a moderate decrease in expression for DHCAECs cultured in 10.5mM 
glucose media compared to the control and the 25.5mM glucose media. This resulted in 
virtually no difference in expression between cell types at this glucose concentration for 
PECAM. The 10.5mM glucose media groups were inconsistent with the trends for both 
cell types for RAGE expression, and for DHCAECS for eNOS expression. This may be 
attributed to the fact that 10.5mM of glucose is relatively conservative concentration to 
represent a hyperglycemic environment, as concentrations nearing 10mM are considered 
representative of blood glucose levels associated with diabetes
 
[31]. Due to the 
complexity of the diabetic disease process, this conservative glucose level may not 
prompt the same responses in either HUVECs or DHCAECs as expected in a 
hyperglycemic environment. Another possibility for these inconsistencies may stem from 
the production of the glucose solution used to supplement cell media. This solution was 
prepared from 18mΩ water and solid glucose (Sigma Aldrich, St. Louis, MO). This 
process has a likelihood of human error throughout the process of weighing and 
combining the glucose with water. The concentration for the glucose solutions were most 
likely different from the theoretical values used to perform the calculations. There were 
also challenges with sterilizing this glucose solution, including determining how to 
sterilize the solution. Ultimately, the glucose solution had to have a low enough 
concentration such that when sterilized in the autoclave, the glucose did not burn; 
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however, heating solution to past the boiling point of water could alter the volume which 
may also have contributed to error in glucose concentrations. This source of error can be 
minimized, or even eliminated, through the use of sterile glucose solution acquired from 
a reliable source that has been analyzed to ensure accurate concentration values.  
Limitations of this preliminary study include the static, 2-dimensional nature of 
the culture conditions, as well as the minimal concrete data attained from 
immunofluorescence analysis. Ideally, the immunofluorescence observations could be 
used to compare the phenotypic response versus the nuclear, mRNA, response of 
endothelial cells exposed to high glucose culture conditions. In this preliminary study, it 
was found that immunofluorescence data is not specific or sensitive when imaged using 
widefield fluorescence microscopy; however, due to time constraints and available 
resources, improved images could not be acquired from confocal microscopy.  
The goal of the tissue engineering lab at Cal Poly is to produce a blood vessel 
model that accurately represents certain aspects of blood vessels in vivo. This preliminary 
study was conducted on cells cultured in static conditions in a 2-dimensional monolayer. 
First, the static nature of these culturing conditions may prevent the equal distribution of 
glucose through the cell flask. Once all the local glucose is consumed, there are no means 
for the redistribution of media once cells are fed or passed, resulting in a local 
environment that may not continue to have an elevated glucose concentration. This may 
result in skewed gene expression data as glucose may no longer be present to activate the 
processes persistent in diabetes. In future studies, this may be addressed by continually 
monitoring glucose concentration in the cell flasks and in the bioreactor and adding 
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sterile glucose solution as necessary to maintain the desired levels of glucose 
concentration. 
Secondly, it has been established that 3-dimensional (3D) culturing systems are 
superior to 2-dimensional (2D) culturing systems due the ability of 3D cell culturing to 
better replicate physiological systems and provide more predictive data for in vivo tests
 
[60]. A key difference between the 2D and 3D culture conditions for the study of diabetes 
in vitro is the differences in cellular responses due to the spatial organization of the cell 
surface receptors (i.e. PECAM) that take part in cell-cell and cell-extracellular matrix 
(ECM) interactions. The physical interactions between cells with each other, the ECM, 
and their microenvironment in 3D culture affects cellular functions, including cell 
proliferation, differentiation morphology, and protein and gene expression
 
[60]. The 
preliminary study was performed using 2D culturing conditions; however, to better 
mimic in vivo conditions in vitro the final study was completed with 3D culture 
conditions.  
 
3.5 Conclusion 
The aim of this preliminary study was to determine an optimal glucose concentration to 
use in the construction of a diabetic BVM. This study was also used to verify the updated 
qPCR protocol that was originally established for the lab. This preliminary study utilized 
two methods of analysis to establish a protocol for the implementation of a high glucose 
cell media for culturing endothelial cells to be cultivated in BVMs. Although 
immunofluorescence is commonly used in the tissue engineering lab for analysis of 
completed BVMs, this study utilized this analysis with disappointing results. There were 
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numerous drawbacks of immunofluorescence, including that only qualitative, subjective 
observations could be made regarding the presence of PECAM. The utility of 
immunofluorescence is better observed in studies identifying multiple cell types or the 
spatial organization in a more complex system, like a BVM. However, the use of 
immunofluorescence confirmed the presence of cells at the completion of treatment, 
demonstrating the feasibility of adding glucose to the cell media without causing 
extensive apoptosis.  
Gene expression analysis demonstrated significant differences due to cell type, 
and – to a small extent – glucose concentration in cell media. The application of the gene 
expression analysis protocol was successful, as observed by the procurement of quality 
data. The analysis of this data revealed trends in gene expression that were not expected; 
however, potential sources of error were identified along with changes that were applied 
to the following experiment in chapter 3. These changes included using a sterile glucose 
solution with a known and verified concentration, and eliminating the 10.5mM glucose 
treatment. The 10.5mM was originally chosen as a conservative increase in glucose 
concentration because it was unknown how well the HUVECs and DHCAECs would 
survive in the elevated glucose media treatments. From the preliminary study, there were 
irregularities found in the gene expression data for this treatment group and the 
determination that this concentration may not accurately reflect hyperglycemic glucose 
levels in vivo. For further studies, this treatment was removed. 
The next chapter discusses the expansion of this study to include the 3D culturing 
of HUVECs and DHCAECs, grown in media with elevated glucose concentrations, in a 
BVM setup. A BVM study was performed to further characterize aspects of the diabetic 
60 
 
blood vessel model. To increase the sample size for more accurate gene expression 
analysis, biological replicates of each cell type and treatment combination were included 
in addition to technical replicates for each qPCR.   
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Chapter 4: Applying High Glucose Conditions to HUVECs and DHCAECs in Tissue 
Engineered Blood Vessel Mimics 
 
4.1 Introduction 
In chapter 2 it was established that there are significant differences in gene expression for 
healthy (HUVECs) and diabetic (DHCAECs) endothelial cells cultured in vitro, as well 
as for some of the different levels of glucose concentration. The preliminary study also 
demonstrated that the DNA primers chosen for qPCR analysis were satisfactory and 
functional in the application of the protocol for gene expression analysis.  
As discussed in chapter 3, the results from gene expression analysis were not as 
expected; however, it was hypothesized that by introducing the cells into a dynamic 3-
dimensional model these results may change and more accurately reflect the proposed 
disease processes that occur in endothelial cells in diabetes. The blood vessel mimic 
construct somewhat more accurately reflects anatomical geometry and shear forces 
experienced in vivo as compared with the 2-dimensional, static culture used in the 
preliminary study. Based on previous studies comparing differences in 2D and 3D culture 
conditions, it is shown that 3D culture conditions better replicate physiological systems 
and provide more predictive data for in vivo tests
 
[60]. Due to these findings, the final 
study was completed using 3D culture conditions using the bioreactor set up for blood 
vessel mimics to best replicate in vivo physiologic conditions that may affect gene 
expression and cell proliferation.  
The same analysis methods were used on BVMs as in the preliminary study, with 
the addition of SEM imaging. SEM imaging has been used previously to evaluate the 
morphology of the endothelial lining in the lumen of BVMs
 
[61].  
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4.2 Materials and Methods 
HUVECs and DHCAECs were initially cultured and expanded using the same protocol 
described in chapter 2. To avoid any complications that may have been due to the glucose 
solution used in the preliminary study, 20% w/w (1.1935M) sterile glucose solution 
(AMRESCO, E545-100ML, Solon, OH) was used to produce cell media with an elevated 
glucose concentration of 25.5mM by adding 8.56mL of glucose solution to 500mL of 
prepared endothelial cell media. The glucose treatment was introduced to cells in the 
T225 culture flasks 6 days prior to application of cells to BVM culturing conditions. 
Once the cells were introduced to the BVM culture conditions, the glucose treatment was 
continued using bioreactor media – with 9.750mL of 20% w/w sterile glucose solution 
added to 569.4mL of media for the high glucose condition.  
 
4.2.1 BVM Set Up 
Two groups of 6 BVMs were cultivated at a time due to the number of sterilized 
bioreactor chambers available. The first group consisted of DHCAECs at passage 5 at 
approximately 90% confluence in T225 flasks. One T225 was used per BVM construct. 
This first set of BVMs contained 3 BVMs treated with high glucose (25.5mM) cell media 
and 3 BVMs cultivated with normal (5.5mM glucose) cell media. The second group of 
BVMs consisted of HUVECs at passage 6 at approximately 95% confluence in T225 
flasks, with one flask used per BVM. Due to time constraints and the HUVECs not 
reaching confluency at passage 5 in three T225 cell flasks, the HUVECs were unable to 
be passed into six T225 cell flasks before the glucose treatment needed to be introduced 
to maintain the same time frame – 6 days prior to BVM introduction – as the DHCAEC 
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group of BVMs. Therefore, the high glucose treatment was introduced to two of the T225 
flasks of HUVECs and the remaining T225 flask of HUVECs was treated with the 
control glucose media. After the glucose treatment was introduced, the three T225 flasks 
of HUVECs were passed at a 1:2 ratio to obtain the six T225 cell flasks needed for BVM 
set up. This resulted in the second set containing 4 BVMs cultivated in high glucose cell 
media and 2 BVMs cultivated in normal cell media.  
The methods used to cultivate BVMs have been previously developed and 
described
 
[62]. In summary, 75:25 PLGA electrospun scaffolds were mounted to fittings 
and sterilized in 70% EtOH for 30 minutes. The scaffolds were then flushed with DCF-
PBS, followed by conditioning media. Scaffolds were then mounted on fittings in an 
ethylene oxide sterilized chamber, which allowed for the connection to a circuit of 
tubing. This circuit connected the chamber to a reservoir of media and passed through an 
8-roller peristaltic pump to provide flow of media through the circuit. Conditioning 
media was pumped through scaffolds for approximately 24 hours prior to sodding of 
cells. 
For this experiment, normal conditioning media was used for all scaffolds. Once 
conditioning was completed, the media in the chamber and reservoirs was exchanged for 
the appropriate cell media for each treatment group.  
 
4.2.2 Take Down and Evaluation 
Three days after sodding cells in the BVM construct, the BVMs were removed 
from the bioreactor chamber and gently flushed with DCF-PBS. Approximately 1cm of 
the BVM was cut transversely from the proximal portion and fixed in 10% formalin, and 
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used for immunofluorescence. The remainder of the BVM was cut longitudinally. For 
each treatment group, one longitudinal section was fixed in 2.5% glutaraldehyde, dried in 
ethanol solutions, placed in a desiccator for 24 hours and used for SEM analysis. En face 
SEM images were obtained for one biological replicate of each treatment group. The 
SEM images were obtained using a standardized protocol. 
Immunofluorescence samples were removed from formalin and embedded in 
TissueTek OCT and frozen quickly using liquid nitrogen. These blocks were sectioned 
transversely using a cryostat maintained at -20°C. Cross-sections 20µm-thick were 
obtained and stored on slides at -20°C prior to staining. These samples were stained using 
the protocol previously discussed in chapter 3. 
The remainder of the longitudinal BVM was rinsed with DCF-PBS to remove 
remaining cell media, and used immediately for gene expression analysis via qPCR. 
BVM sections used for gene expression were rinsed a second time with DCF-PBS and 
then placed in a lysis buffer and vortexed for 2 minutes to release cell contents and 
homogenize cells in the BVM. This cell lysate was then used to isolate RNA as 
previously described in chapter 2.  The isolated RNA was assessed, and used in reverse 
transcription to obtain cDNA using the appropriate volume for each RNA, determined by 
equation 2.1 and the data presented in appendix L. Complementary DNA obtained for 
each biological replicate was evaluated with real-time qPCR following the same 
specifications as the preliminary study. Due to the number of samples obtained, two 
plates were needed to run all samples, shown in the plate templates in appendix J.  
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4.2.3 Statistical Analysis 
The evaluation of gene expression was determined using the same methods described in 
the preliminary study. Due to the addition of biologic replicates for each experimental 
group, the mean abundance data included all biologic and technical replicates for each 
experimental group.  
 
4.3 Results 
The production of BVMs is a sensitive process that has numerous opportunities for error. 
Fortunately, the inclusion of biological replicates mitigated the loss of all data for any of 
the treatment groups. In the first group of DHCAEC BVMs, one of the BVMs cultivated 
in control media fell off the fitting during cell sodding resulting in the loss of cells from 
the construct and was not used for analysis due to the lack of cells that remained in the 
BVM.  
 
4.3.1 Immunofluorescence 
Similar to the preliminary study, a representative image is presented for each treatment 
group for BBI, PECAM, and a composite of the two images were created using ImageJ 
Software, at 10 times objective magnification.  
It should be noted that the orientation of each cross-section varies, and for 
clarification of BVM orientation the luminal side is noted by the asterisk. In the 
immunofluorescence images for the HUVEC BVMs, the PECAM stain is noticeably 
brighter and more prevalent in the group treated with 25.5mM glucose media as 
compared to the control glucose in Figure 30. The opposite appears to be true in the 
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immunofluorescence images for the DHCAEC BVMs in Figure 31, where it was noted 
that the group treated with control glucose media had a brighter and more widespread 
PECAM stain than the group treated with high glucose media. 
 
 
  
 
  
 
 
Figure 30: BVMs cultivated with HUVECs in control (A-C) and 25.5mM of glucose (D-F). (A, D) BBI staining of BVM cross-
sections. (B, E) PECAM staining of BVM cross-sections. (C, F) Composite image of both immunofluorescence stains. 
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Figure 31: BVMs cultivated with DHCAECs in control (A-C) and 25.5mM of glucose (D-F). (A, D) BBI staining of BVM cross-
sections. (B, E) PECAM staining of BVM cross-sections. (C, F) Composite image of both immunofluorescence stains. 
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4.3.2 SEM Imaging 
A representative image is presented for each treatment group at 50x and 500x 
magnification. SEM images of all treatment types revealed a very minimal presence of a 
cell lining on the scaffold, with even less coverage in the groups treated with high 
glucose media compared to those in control media, as seen in Figure 32B and D versus A 
and C, respectively. This is easier seen in the DHCAEC BVMs at 500x magnification 
images in Figure 33.  
 
Figure 32: SEM images obtained at 50x magnification of BVMs cultured with HUVECs 
in control media (A), HUVECs in high glucose media (B), DHCAECs in control media 
(C), and DHCAECs in high glucose media (D). 
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Figure 33: SEM images obtained at 500x magnification of BVMs cultured with 
DHCAECs in control media (A) and DHCAECs in high glucose media (B). 
4.3.3 Gene Expression 
From the RNA assessment performed prior to cDNA synthesis, it was found that a BVM 
from the DHCAEC group that received the elevated glucose treatment and a BVM from 
the HUVEC group that received the elevated glucose treatment did not have an A260/280 
value within the acceptable range, and was consequently removed from further data 
analysis.  
 
4.3.3.1 Quality Assessment 
The amplification and dissociation curves for each qPCR run were used to verify the 
efficiency and products of PCR amplification. Due to the need for two plates to run all 
the samples, plate 1 was all samples from the first group of BVMs using DHCAECs and 
plate 2 was all samples from the second group of BVMs using HUVECs.  
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GAPDH 
The amplification curves, provided in Figure 34, revealed some amplification of the 
NTC. The NTC also had primer dimer formation that was revealed in the dissociation 
curves in Figure 35. One well from a BVM cultivated with DHCAECs in control media 
did not have adequate amplification efficiency and was removed from data analysis. 
 
 
Figure 34: Amplification curves for plate 1 (A) and plate 2 (B) for GAPDH. 
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Figure 35: Dissociation curves for plate 1 (A) and plate 2 (B) for GAPDH. 
 
PECAM - The amplification curves for PECAM, provided in Figure 36, revealed 
adequate efficiency for all samples except for one well associated with a BVM with 
DHCAECs in high glucose, two wells from a BVM with HUVECs in normal media – the 
control group, and one well from a HUVEC with glucose. The dissociation curves, seen 
in Figure 37, confirmed the poor quality of the listed wells, as well as showed a single 
PCR product for the remaining samples and no primer dimer formation in any sample. 
The data obtained from the listed wells were omitted from further analysis. 
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Figure 36: Amplification curves for plate 1 (A) and plate 2 (B) for PECAM. 
 
Figure 37: Dissociation curves for plate 1 (A) and plate 2 (B) for PECAM. 
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RAGE - The amplification curves, provided in Figure 38, showed adequate amplification 
efficiency with the exception of two wells associated with a HUVEC control BVM, and 
one well associated with a glucose treated HUVEC BVM. This observation was 
confirmed by the formation of non-desired PCR product in the dissociation curves, 
shown in Figure 39, for the listed wells and the data for these wells were subsequently 
omitted. The remaining wells showed formation of a single, desired PCR product.  
 
 
Figure 38: Amplification curves for plate 1 (A) and plate 2 (B) for RAGE. 
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Figure 39: Dissociation curves for plate 1 (A) and plate 2 (B) for RAGE. 
 
eNOS - The amplification curves, provided in Figure 40, showed that all samples had 
adequate PCR efficiency except for a single well associated with a BVM cultured with 
DHCAECs in elevated glucose media. The dissociation curves in Figure 41 revealed that 
all samples produced a single PCR product.  
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Figure 40: Amplification curves for plate 1 (A) and plate 2 (B) for eNOS. 
 
Figure 41: Dissociation curves for plate 1 (A) and plate 2 (B) for eNOS. 
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4.3.3.2 Quantitative Analysis 
PECAM - The statistical analysis of PECAM gene expression did not reveal any 
significant differences between the treatment groups, as seen in Figure 42; however there 
is a notable trend. PECAM expression was increased in DHCAECs compared to 
HUVECs regardless of glucose treatment. The glucose did not appear to have a large 
effect on HUVECs, but there was an increase in PECAM expression in DHCAECs 
cultivated in high glucose conditions compared to the control media. 
 
Figure 42: Relative abundance of PECAM for each treatment group. 
 
RAGE - The relative expression of RAGE was significantly different between HUVECs 
that were cultured in control media compared to high glucose media as shown in Figure 
43. There was also a significant difference in RAGE expression between HUVECs and 
DHCAECs grown in control media, while RAGE expression in HUVECs and DHCAECs 
grown in high glucose media were relatively similar. Finally, there was also a significant 
difference between HUVECs in control media and DHCAECs in high glucose media.  
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Figure 43: Relative abundance of RAGE for each treatment group, where *p<0.05 and 
**p<0.01. 
eNOS - eNOS expression was found to be significantly different between cell types 
cultured in either control media or high glucose media, as shown in Figure 44. 
Specifically, there was a significant increse in eNOS expression between HUVECs 
cultured in high glucose media and DHCAECs cultured in high glucose, as well as 
between media HUVECs cultured in control media and DHCAECs cultured in control 
media. There was also a significant difference in eNOS expression in DHCAECs cultured 
in control media versus high glucose media, with the high glucose condition showing 
lower eNOS exporession. Finally, there was a significant difference between HUVECs in 
control media and DHCAECs in high glucose media, with the high glucose DHCAEC 
condition expressing higher eNOS.  
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Figure 44: Relative abundance of eNOS for each treatment group, where *p<0.05. 
 
4.4 Discussion 
From the evaluation of the blood vessel mimics, it is evident that there are differences 
between using HUVECs and DHCAECs, as well as using media with added glucose to 
recreate the hyperglycemic condition diabetic blood vessels experience in vivo. From the 
immunofluorescence and SEM images, it was noted that cell deposition on and within the 
PLGA scaffolds did occur, although the cells were sparsely distributed with no areas of a 
cell “lining”. The SEM images showed minimal cell deposition within the lumen of the 
scaffold, which may be due to poor handling of the specimens throughout the fixing and 
drying process. This could have been minimized by including more than one sample of 
BVM for each experimental group. Another possibility for poor cell coverage could have 
been not using enough cells for sodding each BVM, this could be mitigated by using 
more cells during the sodding of the BVMs. For the diabetic cells and the groups treated 
with high glucose media, there is the potential that disease processes associated diabetes 
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and exposure of endothelial cells to elevated glucose concentrations could have affected 
cell functions, especially those associated with adhesion proteins [33, 41].  
The immunofluorescence images show cell presence primarily in the lumen of the 
scaffold, which is consistent with previous analysis of BVMs produced in the Cal Poly 
Tissue Engineering lab. There was some migration of cells into the scaffold, but it was 
not substantial. During the course of taking the immunofluorescence images, it was 
noticed that the PLGA scaffold produces some background fluorescence when samples 
were observed under the widefield fluorescence microscope. An unrelated concurrent 
study being performed in the Tissue Engineering lab had similar results when imaging 
the same stains using confocal fluorescence microscopy. Unfortunately, a solution for 
this was not found during this study; therefore, the immunofluorescence images used in 
this study should be interpreted with the knowledge that the results may not accurately 
represent the amount of PECAM present. This supports the conclusion drawn in the 
preliminary study that immunofluorescence may not be as useful in studies that only 
utilize one cell type.  
Scanning electron microscopy also revealed very sparse endothelial cell coverage 
in the BVMs for all experimental groups. It appeared that the cell coverage for the 
HUVECs and DHCAECs grown in control media were slightly more confluent than the 
cell coverage for the HUVECs and DHCAECs grown in high glucose media. This may 
be explained by an observation made in the preliminary study, that the cells grown in 
high glucose media tended to be less confluent in cell flasks when grown for the same 
period of time. This may also be indicative of apoptosis caused by ROS overproduction 
by endothelial cells exposed to elevated glucose conditions
 
[57]. Although this is not 
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ideal for endothelial confluency, it is consistent with endothelial cell responses to high 
glucose conditions in diabetes. 
From the gene expression analysis of the BVMs, it appeared that cell type and 
media glucose concentration are both important factors to consider in developing a 
diabetic BVM model. Although there were no significant differences in PECAM 
expression, an upward trend was evident from HUVECs to DHCAECs, as well as from 
control media to high glucose media. This finding is consistent with the processes 
discussed in chapter 1 that found PECAM expression in HUVECs was not altered when 
cultured in high glucose conditions compared to normal glucose conditions [41].  
For cells cultured in high glucose media, there was a significant increase in RAGE 
expression compared to cells cultured in the control media. This is a promising finding 
for simulating diabetic processes in the BVM. The production of advanced glycation end 
products (AGEs) occurs in endothelial cells exposed to an excess of glucose, and when 
AGEs bind to their receptor (RAGE), there is an increase in the production of reactive 
oxygen species (ROS) [43]. The increase in ROS causes oxidative stress within the 
vessels, propagating mechanisms responsible for the development of endothelial 
dysfunction in diabetics. Although both cell types exhibited this increase in RAGE 
expression, there was also a significant increase in RAGE expression between the two cell 
types in control media, which suggests that DHCAECs behave differently than HUVECs 
in the 3D culture condition. 
The eNOS expression data showed a significant increase in expression for 
DHCAECs cultured in control media compared to HUVECs in control media, as well as 
DHCAECs cultured in control media compared to DHCAECs cultured in high glucose 
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media. Although it was expected that eNOS expression would increase in DHCAECs 
compared to HUVECs, it was surprising to see increased eNOS expression in the 
DHCAECs in control media rather than in high glucose media. There are several possible 
reasons for this: (1) introduction of endothelial cells to 3D dynamic culture conditions 
and (2) the lack of other cell types in the model. It has been shown that endothelial cells 
exposed to shear stress, such as flowing media, have increased activation of PECAM, 
which controls an alternative signaling pathway that increases eNOS activity
 
[63]. By 
adding the cells into 3D cultivation in BVMs along with peristaltic flow of cell media, 
there may have been multiple signaling pathways initiated – since the presence of 
PECAM is likely due to the increased expression shown above.  
Also, this model only incorporates endothelial cells, but in vivo nitric oxide (NO), 
produced by eNOS activity, interacts largely with vascular smooth muscle cells(VSMCs), 
causing vasodilation
 
[26]. It has been shown that vascular smooth muscle cells (VSMC) 
not only respond to NO but can also produce it [64]. Stimulation of VSMC induces NO 
release from these cells by stimulating the expression of an inducible nitric oxide 
synthase (iNOS) isoform, thus creating a negative feedback mechanism by decreasing the 
expression of eNOS [64]. This shows the importance of VSMC in the regulation of eNOS 
protein expression in endothelial cells and the involvement of VSMC in the regulation of 
inﬂammation-related endothelial dysfunction [64]. In diabetic patients, there are signaling 
pathways involving inflammation, endothelial dysfunction, and VSMCs – which are not 
included in this study, but are all important in creating an in vitro environment that 
accurately represents a diabetic blood vessel.  
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 Overall, this BVM study showed that 3D culturing conditions of HUVECs and 
DHCAECs differs from 2D culturing conditions, as shown by the gene expression results 
reflecting diabetic processes. This larger study also included more replicates for each 
experimental group, and allowed for better statistical analysis. 
4.5 Conclusion 
 
The aim of this study was to improve upon the previous diabetic blood vessel mimic 
produced in the Cal Poly Tissue Engineering Lab by including the addition of a high 
glucose environment. There were also protocol changes that were implemented based on 
the findings in the preliminary study, specifically using a pre-made sterilized glucose 
solution to add to the cell media to create an elevated glucose environment, eliminating 
the middle range glucose concentration group, and incorporating the 3D culturing 
condition by completing a BVM set-up with the experimental groups. The BVMs were 
then evaluated using immunofluorescence, SEM and qPCR gene expression. The 
immunofluorescence and SEM analysis suggested that the implementation of high 
glucose cell media is feasible for endothelial cell deposition in the BVM. Gene 
expression data was consistent with previous studies for PECAM expression in both the 
DHCAEC and HUVEC groups, and both the high glucose and normal glucose groups, 
which confirms the ability of qPCR analysis to be applied to the BVM set up. The gene 
expression results for RAGE and eNOS are mostly consistent with prior studies that show 
differences in expression for high glucose conditions compared to normal glucose 
conditions, as well as for diabetic cells compared to healthy cells [45, 65, 66].  
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This is a promising foundation for applying gene expression analysis in BVM studies to 
determine if the pathophysiologic processes of endothelial dysfunction associated with 
diabetes are occurring in vitro.   
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Chapter 5: Discussion and Conclusion 
 
 
5.1 Summary and Aims of the Thesis 
Diabetes and coronary artery disease are highly correlated [4, 7, 8]. With the 
hyperglycemia that accompanies diabetes, there are multiple mechanisms that are 
activated that contribute to the progression of vascular disease, namely endothelial 
dysfunction. The devices used to treat vascular disease have not been well-tested for 
efficacy in diabetic patients. Although preclinical diabetic models exist, such as 
streptozotocin-induced diabetic rats and mice, spontaneously mutated rats such as Zucker 
Diabetic Fatty Rats (ZDF), genetically modified mice models, diabetic Yucatan 
miniswine, and streptozotocin-induced diabetic domestic pigs, there are limitations to 
these models, and the medical device industry would benefit from earlier stage diabetic 
testing environments [19, 20, 21]. In the Cal Poly Tissue Engineering lab, blood vessel 
mimics are created to test intravascular devices in vitro. In order to facilitate testing of 
intravascular devices intended for use in diabetic patients, a diabetic BVM was 
previously created using diabetic human coronary artery endothelial cells (DHCAECs) 
and diabetic human coronary artery smooth muscle cells (DHCSMCs) [30, 67]. Although 
this model demonstrated the ability to apply diseased cell types to the BVM set up, there 
was a lack of analysis to demonstrate if the diabetic BVM accurately modeled diabetic 
disease processes.  
The first aim of this thesis – to establish a protocol for qPCR analysis of BVMs 
cultivated with HUVECs and DHCAECs– was accomplished by performing a 
preliminary study of primer verification for qPCR. From this preliminary study, it was 
found that the selected genes of interest and the reference gene chosen had at least one 
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accompanying DNA primer that produced efficient PCR amplification and a single, 
desired PCR product. From these findings, the optimal DNA primer – of the primers 
tested – was selected for each gene of interest and implemented in the subsequent studies. 
This study also established that PECAM, RAGE, and eNOS are suitable genes of interest 
– due to their involvement in the pathophysiology of endothelial dysfunction in relation 
to diabetes and hyperglycemia – and were expressed in both HUVECs and DHCAECs, 
cultured in either normal glucose concentration media or high glucose concentration 
media. GAPDH was also determined to be an appropriate reference gene for qPCR data 
analysis because it was unaffected by differences in cell type or experimental treatment.  
The second aim of this thesis was to improve upon the diabetic BVM by 
developing and implementing an in vitro hyperglycemic condition through the addition of 
glucose to cell culture media. This was investigated in a preliminary study using a normal 
glucose concentration, a mildly elevated glucose concentration of 10.5mM, and a high 
glucose concentration of 25.5mM in cell media to culture HUVECs and DHCAECs in 
static culture conditions in cell flasks. From this study, it was determined that a 
concentration of 25.5mM of glucose elicits a measurable change in gene expression from 
endothelial cells without causing widespread apoptosis. This glucose concentration was 
then used to produce a “diabetic” environment for culturing BVMs.  
Using the glucose concentration of 25.5mM established in the preliminary study, 
BVMs were cultured with either HUVECs, or DHCAECs and in either control, or high 
glucose cell media. Two, three, or four biological replicates – individual BVMs – were 
produced for each treatment group to increase the sample size for qPCR analysis. 
Through immunofluorescence and SEM imaging analysis, it was shown that all treatment 
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groups resulted in at least a small amount of endothelial cell deposition throughout the 
lumen of the BVM. This demonstrated the practicality of culturing a BVM with 
DHCAECs in a hyperglycemic model.  
From gene expression analysis, it was found that there were no significant 
differences in PECAM abundance in mRNA of DHCAECs compared to HUVECs, as 
well as in the groups cultured in a high glucose environment compared to those grown in 
control media. This was consistent with a previous study that showed that HUVECs 
cultured in high glucose conditions (30.0 mM) in vitro did not have altered PECAM 
expression compared to HUVECs cultured in normal (5.0 mM) glucose conditions [41]. 
Although there are limited studies on direct comparisons of diabetic and healthy human 
endothelial cells in vitro – especially regarding gene expression of PECAM – it is 
suggested that, due to higher incidence of atherosclerosis in diabetic patients, high 
glucose and insulin levels can promote increased inflammation in cultured endothelial 
cells in a PECAM-dependent matter [68]. This relationship between PECAM and 
inflammation in diabetic patients may explain the trend of increased PECAM abundance 
in the DHCAEC BVMs compared to the HUVEC BVMs. To obtain a better 
understanding of PECAM gene expression in BVMs, gene expression analysis should 
continue to be performed in future BVM studies.   
There was a significant increase in RAGE abundance in mRNA of DHCAECs 
cultured in control media compared to HUVECs cultured in control media, as well as in 
HUVECs treated with high glucose media compared to normal glucose media. These 
results are consistent with research that has shown that RAGE expression increases in 
human aortic endothelial cells incubated in high glucose conditions compared to normal 
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glucose conditions due to hyperglycemia-induced reactive oxygen species (ROS) 
production by the mitochondrial electron transport chain binding to NFκB to the RAGE 
promoter [65]. Additionally, a previous study showed that RAGE expression was 
increased in aortic endothelial cells of streptozotocin-induced diabetic mice as compared 
to non-diabetic mice, which is again consistent with the findings in this study of 
DHCAECs compared to HUVECs [65]. The expression of RAGE in DHCAECs as 
compared to HUVECs, and in cells cultured in high glucose culture conditions compared 
to normal glucose culture conditions was consistent with previous studies, indicating that 
this diabetic model has promise in accurately mimicking diabetic and hyperglycemic 
conditions in vivo. This also shows that both the diabetic condition and hyperglycemia 
are important in recreating pathophysiologic processes in vitro.  
eNOS abundance in mRNA of DHCAECs in control media was significantly 
higher than all other treatment groups; DHCAECs of both glucose treatments were 
significantly higher than the corresponding HUVEC glucose treatment groups. There are 
conflicting studies showing both increased and decreased eNOS gene expression for 
human aortic endothelial cells cultured in high glucose conditions (22.2mM-25mM 
concentrations) for a prolonged time (5-7 days) [45, 66]. Furthermore, it has been shown 
that mouse aortic endothelial cells from a diabetic population had reduced eNOS gene 
expression compared to a control population [66]. The differences in eNOS expression in 
prior studies and this study reveals the complex nature of the factors that affect eNOS 
expression in endothelial dysfunction due to diabetes; however, this highlights the 
importance of including a high glucose culturing condition and a diabetic cell type to 
produce a representative physiologic environment in vitro for diabetic vascular 
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conditions. To improve upon the diabetic BVM produced in this study, future studies 
should include VSMCs due to the important role of VSMCs in the exchange of nitric 
oxide with ECs that affects the expression of eNOS [64]. 
The gene expression findings, along with the observations from the 
immunofluorescence and SEM images, shows that the diabetic BVMs cultured in high 
glucose conditions are significantly different than the “healthy” BVMs that have been 
previously developed in the tissue engineering lab. There appears to be several 
characteristics of these diabetic BVMs cultured with a simulated hyperglycemic 
condition that indicate that disease processes of diabetic endothelial dysfunction are 
occurring in these models.  
 
5.2 Challenges and Limitations 
As previously discussed, the tissue engineered blood vessel mimic construct adequately 
models some, but not all aspects of blood vessels in vivo. In this study, there are several 
major features of biologic blood vessels that are lacking in BVMs that may affect the 
disease process of diabetes, one of which is the lack of cell types other than endothelial 
cells in the BVM. For instance, nitric oxide (NO) interacts with vascular smooth muscle 
cells and results in the alteration of signal transduction pathways involved in the 
progression of endothelial dysfunction – and most likely eNOS mRNA abundance [69]. 
Additionally, there were no immune cells present; therefore, the inflammation pathway is 
not activated in its entirety. Due to the involvement of PECAM with the inflammatory 
response, the lack of these cells may have affected the abundance of PECAM expression 
in mRNA in both endothelial cell types [68].  
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It should also be noted that glucose concentration was not actively monitored 
throughout the BVM set up. Although the cell media was changed frequently during the 
expansion of HUVECs and DHCAECs, once the BVMs were placed in the bioreactors 
and media was pumped through the BVM constructs there was no monitoring of glucose 
concentration. In these set-ups, cells actively consume glucose resulting in the decrease 
of glucose concentration over time, which may have altered the elevated glucose 
environment that was desired. Continuous monitoring and the addition of glucose 
solution to the BVM as necessary would improve the model developed in this study. 
Patients with diabetes have fluctuations in blood glucose levels throughout the day, 
therefore the continuous addition of glucose to maintain a steady glucose concentration is 
not necessary, but the addition of glucose after initial sodding of the cells could reflect 
these changes in blood glucose concentration seen in vivo.   
Furthermore, the power of the statistical analysis was limited by the sample size 
of each study. The first study was limited to triplicate of each sample due to the lack of 
biological replicates; however, the final study that included biological replicates as well 
as technical triplicates was still limited to fewer data points due to the removal of samples 
for poor RNA quality at the time of isolation, as well as removal of qPCR samples if 
primer-dimer formation, inappropriate amplification or multiple qPCR products were 
observed on the amplification or dissociation curves. To increase the number of data 
points in future studies, more samples could be used for each experimental group. For 
those samples with poor RNA quality or did not meet the quality control standards for 
qPCR, this most likely due to improper handling of the samples and contamination, 
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which can be mitigated through proper aseptic technique during preparation and storage 
of the samples.  
Another limitation to this study was the sparse endothelial cell coverage in the 
lumen of the BVMs for all experimental groups elucidated by the scanning electron 
microscopy images. The lack of cells seen in the lumen of the BVMs may have affected 
gene expression data due to the scarcity of cells, which could cause RNA quality to be 
poor due to low concentrations during isolation. There are several possibilities as to why 
there were few cells in the lumen of the BVM: apoptosis caused by ROS overproduction 
by endothelial cells exposed to elevated glucose conditions, adhesion proteins altered by 
glucose conditions, or not enough cells used during seeding of the BVM [57, 70, 71]. 
Although this is not ideal for endothelial confluency, it is consistent with endothelial cell 
responses to high glucose conditions in diabetes and could be addressed in future studies 
by increasing the number of cells used for seeding of the BVM or including VSMCs 
seeded prior to endothelial cells due to the favorable cell-cell adhesion interactions over 
cell-scaffold interactions. 
 
5.3 Future Work  
From the limitations discussed, the diabetic BVM model can certainly be improved. The 
incorporation of smooth muscle cells has already been demonstrated in BVMs created in 
the tissue engineering lab for the healthy cell type; however, the addition of diabetic 
vascular smooth muscle cells in addition to the high glucose culturing condition would be 
a reasonable next step in the development of a more accurate diabetic BVM.  
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As previously mentioned, the qPCR analysis should be repeated on future BVMs using 
the same genes of interest as this thesis because of the effects the interaction of smooth 
muscle cells and endothelial cells have on the gene expression of PECAM, RAGE, and 
eNOS. This also maintains consistency and allows the Cal Poly tissue engineering 
laboratory to accumulate more data on the BVMs being produced.  
 For the qPCR analysis of these cells, the number of genes selected for 
investigation was limited due to the size of the plates used for qPCR; however, moving 
forward with gene expression analysis, there are additional genes that could lead to a 
better understanding of the disease processes involved in diabetes and endothelial cells. 
One gene in particular is vascular cell adhesion molecule (VCAM), which plays a 
regulatory role in anchoring monocytes involved in the inflammatory reaction and 
contributes to the development atherosclerosis, particularly in its early phases
 
[8, 40]. 
This gene has been previously studied and shown to have increased expression in 
HUVECs in hyperglycemic conditions, as well as in alloxan-treated diabetic rabbits [40, 
71]. These elevations are due to AGE-RAGE interactions in the development of 
endothelial dysfunction and as a consequence of cellular oxidant stress and the activation 
of transcription factor NFκB [40, 71]. 
Due to the lack of information garnered from the immunofluorescence images, it 
is suggested that live-dead immunofluorescence staining be performed in the BVMs 
immediately after take down, before fixing cells. This would allow for the observation of 
apoptotic or necrotic activity that may be associated with the diabetic condition. 
Alternatively, a gene that is associated with apoptotic activity, such as anti-apoptotic 
protein B-cell lymphoma 2 (Bcl-2) and pro-apoptotic protein Bcl-2-associated X protein 
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(Bax), could be included in qPCR analysis [70]. These genes would be extremely useful 
for diabetic purposes specifically because it has been shown that there is a significant 
decrease of Bcl-2 and a simultaneous increase in Bax expression when HUVECs were 
cultured in a stable high glucose environment [70].  
 Finally, in addition to glucose, insulin should be investigated as a supplement to 
the cell media. For type 2 diabetes, the inability of cells to utilize insulin leads to the 
hyperglycemic condition. This causes an increase in insulin levels in the blood – or 
hyperinsulinemia. Along with hyperglycemia, hyperinsulinemia is known to cause 
endothelial dysfunction by increasing oxidant stress through increased endothelin-1, 
which induces NAD(P)H oxidase expression and increased generation of superoxide 
anions in human endothelial cells [72]. Insulin is also known to regulate the expression of 
eNOS gene which alters vascular tone, which may lead to endothelial dysfunction in 
diabetics [73]. Thus, it is suggested that adding insulin to replicate modest 
hyperinsulinemia, mimicking fasting hyperinsulinemia of insulin-resistant states – such 
as diabetes mellitus – will better represent the diabetic condition of blood vessels in vitro 
with respect to the pathophysiology of endothelial dysfunction [72].  
 
5.4 Conclusion 
Overall, it was found that qPCR analysis was feasible and applicable to tissue engineered 
blood vessels cultured with HUVECs and DHCAECs. This analysis method allows for 
more in-depth characterization of these BVMs, especially in distinguishing differences 
between the two cell types. 
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 It was also found that a high glucose environment – in addition to incorporating 
diabetic endothelial cells – in the production of BVMs leads to a BVM that has 
significantly different characteristics than the standard “healthy” BVMs previously 
created in the Cal Poly Tissue Engineering Lab. This was confirmed with the use of 
immunofluorescence, SEM imaging, and qPCR analysis. The qPCR analysis of these 
BVMs was somewhat consistent with the proposed hypotheses: PECAM, RAGE, and 
eNOS expression were increased in DHCAECs cultured in a high glucose environment, 
compared to the HUVECs cultured in a normal glucose environment. It was found that 
RAGE and eNOS expression was significantly increased between these treatment groups; 
however, PECAM expression was not significantly increased, but had an upward trend. 
 From these studies, it is suggested that high glucose media should be 
implemented in the production of diabetic BVMs with DHCAECs, as well as including 
vascular smooth muscle cells, for all future studies of the diabetic condition in 
conjunction with tissue engineered blood vessel mimics. qPCR gene expression analysis 
should also be implemented for all future studies of BVMs, as it allows for further 
characterization of the BVMs, and a quantitative analysis of cell function.   
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APPENDICES 
APPENDIX A: Immunofluorescence Staining Protocol for PECAM 
Materials: 
 Samples 
 Secondary antibody – AlexaFluor 488 
goat anti-mouse 
 
 Pap pen 
 Tin Foil 
 
 PBS (phosphate buffered saline) 
 BBI (bisbenzimide) 
 
 Saponin 
 Mounting media 
 
 FBS (fetal bovine serum)  
 Cover slips 
 
 Primary antibody – mouse anti-CD31 
(PECAM) 
 
 Pipettes and tips 
 Waste beakers  
 
Staining Protocol 
1. Label slides and treatments 
2. Prepare about 50ml of PBS 
3. Using the pap pen, draw a thick circle around the sample and let dry for 5 minutes, or 
until dry 
4. Gently apply PBS using a micropipette and wash (2-3 x 5 min) 
5. Permeabilize cells using saponin (1%) for 10 minutes 
6. Gently apply and wash in PBS (1 x 5 min) 
7. Make 10% serum with PBS 
8. Block for 60 minutes at room temperature  
9. Make primary antibody solution (1:500 blocking solution) 
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10. Remove blocking and incubate in primary antibody overnight (~8-10 hours) in the 
fridge 
11. Wash in PBS (3 x 5 min) 
12. Make secondary antibody solution (5μg/ml) in blocking solution 
13. Incubate in secondary antibody for 45-60 minutes at room temperature  
a. WRAP IN FOIL 
14. Wash in PBS (3X 5 min) 
a. Don’t forget foil 
15. BBI (1:400) for 5 minutes 
16. Wash in PBS for 5 min 
17. Mount or prepare for observation 
18. Fluorescence: PECAM shows up in 488 (3, 2) and BBI in 400 (1, 1). 
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Stock 
Final 
Concentration 
Amount of Reagent 
Amount of 
Additional 
Blocking/PBS 
Total ml 
(~200 μl/ 
slide) 
Saponin 1% in PBS (         )𝑡𝑜𝑡𝑎𝑙 𝑚𝑙 ×
10 𝑚𝑔
1 𝑚𝑔
=        mg  
 
 
PECAM 
1° 
(0.5 
μg/μl) 
1*:500 (B) (         )𝑡𝑜𝑡𝑎𝑙 𝑚𝑙 ×
1 𝜇𝑙 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦
0.5 𝑚𝑙
=   μl 
  
α-SMA 1°  
(0.5 
μg/μl) 
1:500 (B) (         )𝑡𝑜𝑡𝑎𝑙 𝑚𝑙 ×
1 𝜇𝑙 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦
0.5 𝑚𝑙
=  μl 
α-mouse 
488  
(2 μg/μl) 
5μg/ml (B) 
(         )𝑡𝑜𝑡𝑎𝑙 𝑚𝑙 ×
2.5 𝜇𝑙 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦
1 𝑚𝑙
= 
μl 
  
α-rabbit 
594  
(2 μg/μl) 
5μg/ml (B) 
(         )𝑡𝑜𝑡𝑎𝑙 𝑚𝑙 ×
2.5 𝜇𝑙 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦
1 𝑚𝑙
= 
μl 
Blocking 
Solution 
10% in PBS (         )𝑡𝑜𝑡𝑎𝑙 𝑚𝑙 ×
100 𝜇𝑙
1 𝑚𝑙
=         μl 
 
 
 
 
 
*May need to be doubled if signal is weak 
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APPENDIX B: Protocol for RNA Isolation from Cultured Cells and BVM Samples 
(SOP7100) 
Purpose: To obtain RNA from a sample of cells either from a culture flask, or BVM. 
Approx. Time:  
1 hour 
Procedure: 
A.  Preparation 
In Bonderson Lab: 
1. Wash hands and put on gloves. 
2. Spray and wipe down working area with 18Ω water. 
3. Wipe down working area, micropipettes, and any other 
tools that will contact the sample with RNAse Zap 
wipes.  
4. Obtain and label (sample name/number) QIA 
shredder, RNeasy spin column, and 2 RNAse-free 1.5 
mL collection tube for each sample. 
4.1. Labeling abbreviations need to be documented in 
lab notebook. 
 
B.  Preparing Cells – Cell Flask 
In tissue engineering lab: 
1. Spray down hood with 70% IPA.  
2. Warm up Trypsin and corresponding amount of media 
needed to deactivate.  
3. Trypsinize cells 
 
Abbreviations: 
BVM – blood 
vessel mimic  
 
Reminders: 
1. When 
working in the 
hood, use 
aseptic 
technique. 
2. Balance 
centrifuge 
prior to each 
spin. 
3. Isolate RNA 
from BVMs 
as soon as 
possible after 
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take down to 
minimize any 
loss. 
4.If there is a 
device, leave 
it in the BVM 
during cell 
collection. 
3.1. Aspirate media from flask 
3.2. Waterfall DCF-PBS and rinse.  
3.3. Aspirate DCF-PBS 
3.4. Add appropriate amount of Trypsin (see Table 1: 
Volume of Trypsin Required) 
 
Table 1: Volume of Trypsin Required 
Flask Size Volume of Trypsin (mL) 
T25 1mL 
T75 3mL 
T225 9mL 
 
3.5. Incubate for several minutes. 
3.6. “Slap the flask” to loosen cells. 
3.7. Use the microscope to ensure cells are removed 
from flask. 
3.8. Deactivate with media (ratio depends on cell type) 
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 4. Transfer cell solution from flask to labeled 50mL 
conical 
5. Centrifuge conicals for 4 min. at setting 4. 
6. Carefully aspirate solution above cell pellet. 
7. Add approx. 5mL DCF-PBS to cell pellet and re-
suspend.  
8. Repeat steps 5 & 6.  
9. Submerge conical with cell pellet in liquid nitrogen 
for approx. 15 seconds, until frozen throughout. 
10. Transfer to Bonderson Lab, or store at -80°C 
 
C. Preparing Cells – BVM 
In Bonderson Lab: 
1. Record approximate dimensions of BVM section. 
2. Rinse BVM in DCF-PBS to remove all traces of 
media. 
3. Transfer BVM to 1.5mL collection tube.  
D. RNA Isolation – all sample types 
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Materials:  
1. Trypsin & cell 
media (for cell 
flask 
isolation) 
2. Sterile pipet 
tips 
3. RNEasy Mini 
Kit (Qiagen) 
- RNeasy 
spin 
columns 
- QIA 
shredder 
spin 
columns 
- 1.5mL 
&/or 
2.0mL 
collection 
tubes 
- Buffer 
RLT 
In Bonderson Lab: 
1. Add 600uL of Buffer RLT to sample (see Table 2). 
1.1. Pipette up and down to mix. 
1.2. Vortex tube for 2 minutes. 
*Note: For BVMs, add half the volume of Buffer RLT 
and perform step 1 twice. 
 
2. Transfer all cell lysate to QIA shredder spin column.  
2.1. Centrifuge at 16.1 x 104 rcf for 2 minutes. 
3. Add 600uL of 70% ethanol to flow through from QIA 
shredder spin column. 
3.1. Pipette up and down to mix. 
4. Transfer 600 uL of flow through solution to RNeasy 
spin column.   
4.1. Centrifuge at 16.1 x 104 rcf for 30 seconds. 
4.2. Discard flow through in waste. 
4.3. Repeat step 4 for remaining flow through from 
QIA shredder spin column.  
5. Add 700uL RW 1 washing buffer to RNeasy spin 
column 
5.1. Centrifuge at 16.1 x 104 rcf for 30 seconds. 
5.2. Discard flow through in waste. 
6. Add 500uL Buffer RPE to RNeasy spin column 
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- Buffer 
RPE 
- RW1 
washing 
buffer 
- RNase-
free water 
4. 70% ethanol 
5. 18Ω water 
6. DCF-PBS 
7. RNAse Zap 
Wipes 
6.1. Centrifuge at 16.1 x 104 rcf for 30 seconds. 
6.2. Discard flow through in waste. 
7. Add 500uL Buffer RPE to RNeasy spin column 
7.1. Let sit for 5 minutes 
7.2. Centrifuge at 16.1 x 104 rcf for 2 minutes. 
7.3. Discard flow through in waste. 
8. Centrifuge empty RNeasy spin column at 16.1 x 104 
rcf for 2 min. 
9. Change gloves and wipe down with RNAse Zap 
Wipe. 
10. Place RNeasy spin column in new, labeled 1.5mL 
collection tube.  
11. Add 30uL buffer (RNAse-free) water to RNeasy spin 
column. 
11.1. Centrifuge at 16.1 x 104 rcf for 1 minute. 
11.2. Save flow through. 
12. Repeat step 11.  
13. Discard RNeasy spin column in biohazard (RNA will 
be in flow through in collection tube). 
14. Continue with RNA Quality Assessments (SOP7102). 
15. Store RNA at -80°C. 
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E. Clean Up 
1. Discard remaining waste. 
1.1.Spin columns, collection tubes, and pipette tips go in 
biohazard. 
2. Return supplies and reagents to proper location.  
3. Clean working area with 70% IPA.  
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APPENDIX C: Protocol for RNA Assessment (SOP7102) 
Purpose: To assess the quality and determine concentration of isolated RNA. 
Approx. Time:  
10 minutes/sample 
Procedure: 
In Bonderson lab: 
A.  Spectrophotometry – Nanodrop 2000 
1. Open NanoDrop 2000 program on laptop 
2. Select Nucleic Acid 
3. Perform wavelength verification 
3.1. Remove Kim Wipe and lower arm 
4. Select RNA as sample type 
5. Rinse stage with RNAse-free water 
6. Blank spectrophotometer 
6.1. Add 1uL RNAse-free water to the stage 
6.2. Lower arm and select “blank” 
7. Dry stage gently with Kim wipe 
8. Name sample (using normal naming convention) 
9. Add 1uL of sample RNA to stage 
10. Lower arm and click “measure” 
10.1. Record concentration, 260/280, and 260/230 
 
Abbreviations: 
EtBr – Ethidium 
bromide 
TAE – Trisacetate 
EDTA 
Reminders: 
1. Remove gloves 
when using 
NanoDrop 2000 
laptop. 
2. Mark orientation 
of samples in 
electrophoresis 
tray. 
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Materials:  
1. DNAse-free 
pipet tips 
2. 1uL pipet 
3. Agarose 
4. TAE 
5. EtBr 
6. Flask & 
graduated 
cylinder 
7. RNAse-free 
water 
8. Kim Wipes 
9. Loading dye 
10. DNA ladder 
11. Parafilm 
 
values.  
10.2. Repeat measurement twice more (total 3 
values for each sample) 
11. Gently dab stage dry after use. 
11.1. Leave Kim wipe under arm when finished. 
 
In Bonderson or Peterson lab: 
B. Gel Electrophoresis 
1. Measure 50mL TAE 
2. Weigh 0.5g Agarose in weigh boat 
3. Add Agarose to TAE and microwave in 30 second 
intervals until Agarose has dissolved 
3.1. Swirl between intervals 
3.2. Watch carefully to avoid boil over 
4. Add 2uL of EtBr to TAE & Agarose solution 
5. Let TAE & Agarose solution cool 
5.1. Until you can hold your palm to the flask for 
10 sec. 
6. Tape sides of electrophoresis tray to form mold 
7. Pour TAE/EtBr & Agarose solution into mold 
7.1. Place comb into mold 
7.2. Wait for TAE solution to polymerize 
7.3. Remove comb 
 
Equipment: 
1.  Electrophoresis 
tray 
2. Gel comb 
3. Scale 
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4. UV machine & 
camera 
8. Mix sample and loading dye on parafilm or in 
tubes. 
8.1. 2-5uL of sample + 2uL loading dye 
8.2. 2uL of DNA ladder + 2uL loading dye 
9. Pipet samples into gel wells 
10. Fill electrophoresis tray with TAE. 
10.1. Add 1uL of EtBr to positive (red) pool in tray. 
11. Run at 100 V for 1 hour, checking periodically 
12. Turn off power.  
13. Remove gel from tray. 
14. Place gel in UV imaging gel dock. 
15. Turn on camera and gel dock. 
16. Obtain image using filter #3 on gel dock. 
 
Revision History 
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APPENDIX D: Protocol for Reverse Transcription (SOP7103) 
Purpose: To obtain cDNA via reverse transcription of isolate mRNA. 
Approx. Time:  
1 hour (for 
approx. 10 
samples) 
Procedure: 
A. Preparation 
1. Using average concentration obtained in RNA 
assessment, calculate volume of RNA needed. 
1.1. Determine amount of RNA (ng) for duration of 
experiment. 
1.2. 200ng to 1000ng are needed to run qPCR 
1.3. (x ng of RNA) *(1mL/ [RNA ng/nL]) = Volume 
RNA (uL) 
2. Calculate amount of nuclease free water needed. 
2.1. 15uL-Volume RNA = Volume H2O (uL) 
3. Wipe down working area, micropipettes, and any other 
tools with RNAse Zap Wipes. 
 
B.  iScript Transcription 
1. Prepare master mix 
1.1. 4uL of 5X iScript Reaction mix per sample 
1.2. 1uL of RT per reaction 
1.3. Include additional 10% of each reagent for pipetting 
error 
 
Abbreviations: 
RT – reverse 
transcriptase 
 
Reminders: 
1. Keep working 
area and tools 
RNAse free 
(wipe down 
tools 
continually). 
2. Store iScript 
cDNA 
synthesis kit at 
-20°C. 
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Materials:  
1. iScript cDNA 
Synthesis Kit 
- 5X iScript 
Reaction Mix 
- RT 
- RNAse free 
water 
2. Nuclease free 
tubes 
3. Thermal cycler 
tubes 
 
2. Label 1.5mL/2mL nuclease free tubes for each sample. 
3. Add 5uL of master mix to each tube 
4. Add calculated volume of RNA and nuclease free water 
to each tube. 
4.1. Centrifuge briefly  
5. Load samples (20uL) into thermal cycler tubes and cap 
6. Place tubes into thermal cycler. 
6.1. Ensure the lid is securely touching the caps of the 
tubes 
7. Run thermal cycler program, “ISCRPT” 
7.1. 25°C for 5 min (300 sec) 
7.2. 42°C for 30 min (1800 sec) 
7.3. 4°C forever (hold) 
8. After cycling is completed, remove from thermal cycler 
9. Dilute cDNA 1:5 with 80uL nuclease free water 
10. Store cDNA at -20°C 
 
Equipment: 
1.Thermal cycler 
2.Centrifuge 
 
Revision History 
A Michael Gibbons 
Sarah Ur 
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APPENDIX E: Protocol for qPCR (SOP7105) 
Purpose: To prepare and perform qPCR analysis. 
Approx. Time:  
2 hours of prep. 
2 hours to run 
Abbreviations: 
GOI – gene of 
interest 
NTC – non-
template control 
PMM – primer 
master mix 
Procedure: 
A.  Plate & Primer Preparation 
1. Plan plate map (3 technical replicates for each sample 
per GOI + 1 NTC per GOI)  
2. Calculate PMM for each GOI 
2.1. Include 10% for pipetting errors 
2.2. See table for amount needed per well. 
 
Table 1: Primer Master Mix Volumes 
Solution Vol. per Reaction (uL) 
Fast SYBR Green 5 
15uM Forward Primer 2 
15uM Reverse Primer 2 
Nuclease Free Water 7.8 
3. Turn on hood, and let run for at least 1 hour prior to 
use 
4. Spray down hood with ethanol and wipe with Kim 
wipes 
4.1.Spray down each item (pipettes, plate holder, etc.) 
brought into the hood 
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Reminders: 
1. Use aseptic 
technique in 
the hood. 
2. Keep qPCR 
master mix 
cold (on ice 
or in frozen 
tube rack).  
SYBR green 
is light 
sensitive, use 
precautions 
once added to 
PMM. 
5. Prepare PMM in nuclease free tube for each GOI 
B.  PCR Plate Preparation 
1. Place 96-well plate in frozen plate holder 
1.1. Change plate holder out if color change occurs 
2. Pipette16.8uL of appropriate PMM into each well 
3. Pipette 3.2uL of appropriate cDNA into each well 
3.1. Pipette 3.2 uL of nuclease free water for NTC 
wells 
4. Secure plate cover onto 96-well plate 
5. Centrifuge plate briefly 
 
C. qPCR System Set Up 
1. Turn on qPCR 7500 Fast System and connected lap 
top. 
1.1. Open 7500 Fast System software 
2. Name plate, input name and any additional notes for 
plate ID. 
3. Select SYBR Green as detector. 
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Materials:  
1. Fast SYBR 
Green 
2. Fast 96-well 
qPCR plate 
3. Plate cover 
4. 15uM 
primers 
5. Nuclease free 
water 
6. Frozen PCR 
plate holder 
7. Ethanol  
8. Kim wipes 
9. Micropipettes 
Nuclease free 
pipette tips 
3.1. Use ROX as passive reference 
4. Input sample ID and GOI for each well (will help with 
data analysis!) 
4.1. Select action for each well: Standard (for samples), 
NTC, or none (for empty wells) 
5. Place plate in qPCR 7500 Fast System 
6. Use standard run times as listed in table 2. 
6.1. Include a dissociation cycle to the run. 
 
Table 2: Thermal Cycling Times for qPCR 7500 Fast 
System 
Temperature Duration Cycle 
95.0°C 20 secs HOLD 
95.0°C 3 secs HOLD 
60.0°C 30 secs 40 
Dissociation Cycle (Standard Settings) 
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 7. A pop up will notify if run was successful, save the 
document and continue with qPCR Data Analysis.  
 
D. Clean Up & Storage 
1. Discard pipette tips and empty tubes in biohazard 
2. Return supplies to appropriate location 
2.1. Label properly with contact information 
3. Wipe down hood with ethanol and Kim wipes before 
turning off 
4. Store Fast SYBR Green at 4°C after first thaw.  
5. Store qPCR plate at -20°C after each run. 
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APPENDIX F: Protocol for qPCR Data Analysis (SOP7106) 
Purpose: To interpret and quantify qPCR results. 
Approx. Time:  
5-10 minutes 
per sample 
Procedure: 
A. Analyzing qPCR Results on 7500 Real-Time PCR System  
1. Upon completion of a qPCR run, begin by reviewing the 
“Spectra” tab. You are main concern is column “A”, this is 
the column that detects SYBR green fluorescence. Highlight 
all wells for a gene of interest, and slide the “cycle” box 
upwards. You need to verify that fluorescence increases from 
cycle 0 to cycle 40. Figure 1 shows proper fluorescence for a 
gene of interest at 40 cycles. 
 
Figure 1: Spectra for a single gene of interest at 40 cycles. 
 
2. View the “Amplification Plot” tab. “Auto” calculation can be 
performed for Ct; however, you will need to verify the output 
to ensure that it has been analyzed correctly. 
2.1. Baseline should be set for cycles prior to exponential 
amplification that appears almost as a horizontal line. In 
 
Abbreviations: 
 1. Ct - threshold 
cycle 
2. SE - standard 
error 
3. STDEV - 
standard 
deviation 
4. n - sample 
size 
5. s - STDEV of 
ΔCt 
6. GOI - gene of 
interest 
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figure 2, the baseline should be set for cycle 22 to 27. 
2.2. Place the threshold cycle (horizontal green line in figure 
2) in the middle of the linear region. Then click 
“Analyze”. Figure 3 shows the same results after 
analysis. 
2.3. Click File, Export, Results.  
 
Figure 2: Raw amplification plot for a specific GOI. 
 
 
Figure 3: Amplification plot after being analyzed. 
 
3. Next, click the “Dissociation Curve” tab. Ensure that all wells 
containing samples are melting at the same temperature, as 
seen in Figure 4.  
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Figure 4: Ideal dissociation curve for a specific primer. 
 
 
3.1. Make note of any wells that did not have a similar curve, 
or had primer-dimer formation as seen in Figure 5.  
 
Figure 5: Dissociation curve with primer-dimer formation. 
 
 
4. Prior to data analysis, you will want to review the analyzed 
amplification plots for each triplicate set of samples for each 
GOI. You can do this by highlighting the appropriate wells 
on the “Amplification Plot” tab. All triplicate values should 
have similar slopes. Note: Wells with different slopes should 
be considered an outlier and removed from the data set.  
 
primer-dimer 
outlier 
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5. Lastly, you will need to review the dissociation curve for 
outliers and primer-dimer formation, and remove data as 
necessary. 
 
B. Reference Gene Validation 
1. Average triplicate Ct values for each sample for the reference 
gene. 
2. Plot average Ct values for each sample group on a bar chart.  
2.1. Calculate SE using the following equation for the error 
bars: 
𝑆𝐸 =
𝑆𝑇𝐷𝐸𝑉
√𝑛
 
 
3. Perform a one-way ANOVA with a 95% confidence interval 
to ensure there is no significant difference between samples 
for the reference gene. 
3.1. If p <0.05 the reference gene cannot be used for the 
samples. 
 
C. Relative Expression Analysis 
1. Average triplicate Ct values for each sample/gene of interest 
set. 
2. Normalize samples to the appropriate reference gene using the 
following equation: 
referencesampleGOIsample CtCtCt ,,   
3. To obtain ΔΔCt data, an experimental and control group must 
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be analyzed, shown in the formula below: 
controlerimental CtCtCt  exp  
4. Abundance and fold change can then be calculated using the 
following, respective equations: 
CtAbundance  2  
Fold Change = 2
-ΔΔCt
 
D. Calculating STDEV and SE 
1. Calculate STDEV for each for each sample/primer set 
(including the reference gene) 
2. Calculate s using the STDEV of the reference gene and the 
gene of interest: 
𝑠𝐺𝑂𝐼 =  √𝑆𝑇𝐷𝐸𝑉𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒
2 +  𝑆𝑇𝐷𝐸𝑉𝐺𝑂𝐼
2  
3. Calculate SE for the fold change values (for error bars) with 
the equation below: 
𝑆𝐸 =
𝑠𝐺𝑂𝐼
√𝑛
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APPENDIX G: Protocol for Primer Design (SOP7104) 
Purpose: To design primers for reference genes and genes of interest. 
Approximate 
Time: 
10-15 minutes 
per primer 
Procedure: 
1.Go to GenBank: http://www.ncbi.nlm.nih.gov/genbank/  
2. Select “Nucleotide” from the drop-down search menu 
3.Search for the gene of interest, ensure mRNA and Homo 
sapiens (protein) is selected 
4. Select gene and scroll to the bottom of the page to locate the 
sequence 
5. Record the accession number and copy the gene sequence 
6. Go to PrimerQuest: 
http://www.idtdna.com/primerquest/home/index 
7. Copy the sequence into the “Sequence Entry” box at the top 
of the page (it will automatically ignore line numbers) 
8. Input the sequence name 
9. Select “Show Custom Design Parameters” 
a. Select “qPCR Intercalating Dyes (Primers Only) 
b. Set “Primer Size (nt)” to min. 18, optimum 20, and 
max. 22 
c. Set “Primer Tm” to min. 59.0, optimum 60.0 and max. 
61.0 
d. Set “Amplicon Size (bp)” to min. 180, optimum 200, 
 
Reminders: 
1. It is best to 
select an 
mRNA 
sequence that 
spans an 
intron in the 
DNA 
sequence (to 
prevent 
amplification 
of 
contaminated 
DNA in 
qPCR 
reaction) 
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2. The first 
primer set is 
not always 
the best, 
complete all 
primer 
selection 
steps for 
multiple 
primers for 
each gene 
prior to 
making 
selections to 
order. 
3.High 
homology 
with 
different 
variants of 
same gene is 
desirable 
 
and max. 220 
e. Leave all other parameters as is 
f. Click “Get Assays,” PrimerQuest will output 5 sets of 
forward and reverse primers that match input criteria 
g. Select “View Assay Details” for the desired primer set. 
This will open a new page with the forward and reverse 
primers. Copy these sequences. 
10. Go to NetPrimer (leaving the IDT page open): 
http://www.premierbiosoft.com/NetPrimer/AnalyzePrimer
.jsp 
11. Input copied forward and reverse primers, name of 
sequence and an optional description, and click “analyze” 
12. Analyze “Rating” – Ideal rating is around 95% and higher 
for each primer, however not necessary if not possible for 
selected gene 
13. Once a primer set with optimal ratings has been 
determined, go to Primer-BLAST: 
http://www.ncbi.nlm.nih.gov/tools/primer-blast 
14. Enter the selected forward and reverse primers into 
“Primer Parameters” box 
15. Check for homology with non-target genes, if found select 
different primer set from PrimerQuest and repeat for each 
gene 
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High 
homology with 
non-target 
genes is not 
desirable 
16. Once an optimal primer set has been selected, return to 
Primer Quest (Integrated DNA Technologies): 
http://www.idtdna.com/site 
17. Click the box for the forward and reverse primer set that 
meets all the desired parameters and you are ready to 
purchase and click “Add Selected Assays to Cart” 
18. In the pop-up that appears click “Forward and Reverse 
Primers”, then select “Oligos in Tubes” 
19. Confirm assay set and click “Continue” 
20. Change Scale to 25nmol DNA oligo 
21. Change “Purification” to “Standard Desalting” 
22. Name sequence with gene and forward/reverse 
23. Click “Add and Checkout” 
24. Once in cart, click edit on each primer sequence. Change 
“Normalization” to “Lab Ready.” Click “Add to Order” 
25. Note the size of the expected amplicons, record sequence 
and accession number as necessary 
26. Place order, each primer pair should be approximately $20 
Materials: 
1.Computer 
with internet 
access. 
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APPENDIX H: Primer Sets Selected for Verification and Subsequent Amplification 
and Dissociation Curves 
Table 8: Primer sets and characteristics for primer verification study. 
Primer ID Direction Sequence (5’ to 3’) Length 
(bp) 
Homologs 
GAPDH 1 
(NM_001289745.1) 
Forward CGACCACTTTGTCAAGCTCA 20 Self: 4 
Other: 10 Reverse AGGGGAGATTCAGTGTGGTG 20 
GAPDH 2 
(NM_001289745.1) 
Forward GTATGACAACAGCCTCAAGAT 21 Self: 4 
Other: 0 Reverse TAGAGGCAGGGATGATGTT 19 
GAPDH 3 
(NM_001289745.1) 
Forward GTCGGAGTCAACGGATTTG 19 Self: 3 
Other: 0 Reverse TCCATTGATGACAAGCTTCC 20 
BACT 1 
(NM_001101.3) 
Forward CCACCATGTACCCTGCATT 20 Self: 0 
Other: 12 Reverse CGGACTCGTCATACTCCTGC 20 
BACT 2 
(NM_001101.3) 
Forward TGAGATTGGCATGGCTTTAT 20 Self: 1 
Other: 19 Reverse CTTCCTGTAACAACGCATCT 20 
ENOS 1 
(NM_000603.4) 
Forward GTCCTGTGTATGGATGAGTATG 22 Self: 2 
Other: 0 Reverse GCTGTTGAAGCGGATCTT 18 
ENOS 2 
(NM_000603.4) 
Forward TCCCTCGTGTGAAGAACT 18 Self: 8 
Other: 4 Reverse GAGCTGTAGTGGTTGATG 21 
PECAM 1 
(NM_000442.4) 
Forward GCGGTGGGAAGATTACAAGA 20 Self: 1 
Other: 0 Reverse TTTGGTGAGACCCACTTTCC 20 
PECAM 2 
(NM_000442.4) 
Forward CCAGCCCAGGATTTCTTATG 20 Self: 7 
Other: 0 Reverse TCTGCAACACACTGGTATTC 20 
RAGE 1 
(NM_001136.4) 
Forward AGGAGACCAAGTCCAACTAC 20 Self: 10 
Other: 5 Reverse CCTTCACAGATACTCCCTTCT 21 
RAGE 2 
(NM_001136.4) 
Forward AGTCCGTGTCTACCAGATT 19 Self: 10 
Other: 1 Reverse GGTCTGTTCCTTCACAGATAC 21 
RAGE 3 
(NM_001136.4) 
Forward AGCGTGCAGAACTGAATC 18 Self: 8 
Other: 1 Reverse GGCTCTGGTTGTAGAAGAAA 20 
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APPENDIX I: Preliminary Study RNA Assessment and Calculations 
Table 9: RNA isolation data from BVM study. 
Sample A260/280 RNA Concentration 
(ng/µL) 
RNA Volume (µL) 
DHCAEC BVM 1 – 
Normal Glucose Media 
/ 0.4  
1.57 1.5  
1.79 1.7 Insufficient RNA 
DHCAEC BVM 2 – 
Normal Glucose Media 
1.67 14.1  
1.71 11.7  
1.29 20.2 13.04 
DHCAEC BVM 3 – 
Normal Glucose Media 
2.03 17.1  
1.67 28.7  
1.87 17.6 9.46 
DHCAEC BVM 4 – 
High Glucose Media 
1.97 31.1  
1.96 31.3  
1.93 32.3 6.34 
DHCAEC BVM 5 – 
High Glucose Media 
1.13 69.4  
1.52 10.3  
1.56 6.5 12.22 
DHCAEC BVM 6 – 
High Glucose Media 
2.22 13.8  
1.75 21.0  
1.65 22.9 10.39 
HUVEC BVM 1 – 
Normal Glucose Media 
2.26 16.0  
1.95 22.8  
2.06 15.9 10.97 
HUVEC BVM 2 – 
Normal Glucose Media 
2.12 43.3  
2.07 46.8  
2.06 46.2 4.40 
HUVEC BVM 3 – 
High Glucose Media 
2.16 22.9  
2.16 21.6  
2.05 21.6 9.08 
HUVEC BVM 4 – 
High Glucose Media 
2.44 18.3  
2.15 20.0  
2.29 19.6 10.36 
HUVEC BVM 5 – 
High Glucose Media 
1.53 20.9  
/ /  
/ / 9.57 
HUVEC BVM 6 – 
High Glucose Media 
2.21 20.6  
2.13 20.6  
2.29 19.9 9.82 
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APPENDIX J: qPCR Plate Schemes 
 
 
Figure 45: First plate scheme for experiment in chapter 4, where each color 
represents a gene: GAPDH, PECAM, RAGE, and eNOS; rows C and D are 
RNA samples isolated from BVMs composed of DHCAECs and cultured in 
normal glucose media; rows E-G are RNA samples isolated from BVMs 
composed of DHCAECs and cultured in high glucose media; and row H are 
non-template controls.  
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Figure 46: Second plate scheme for experiment in chapter 4, where each color 
represents a gene: GAPDH, PECAM, RAGE, and eNOS; rows A and B are 
RNA samples from BVMs composed of HUVECs and cultured in normal 
glucose media; rows C-F are RNA samples from BVMs composed of 
HUVECs and cultured in high glucose media; and row are non-template 
controls. 
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APPENDIX K: Data and Minitab Statistical Analysis from Preliminary Study 
 
Comparing Glucose Concentrations 
PECAM 
 
Two-Sample T-Test and CI  
 
Sample  N    Mean   StDev  SE Mean 
HUVEC   3  0.0426  0.0203    0.012 
+ Control 
HUVEC   3  0.1642  0.0610    0.035 
+ 10.5  
 
Difference = mu (1) - mu (2) 
Estimate for difference:  -0.1216 
95% CI for difference:  (-0.2814, 0.0382) 
T-Test of difference = 0 (vs not =): T-Value = -3.27  P-
Value = 0.082  DF = 2 
 
Two-Sample T-Test and CI  
 
Sample  N    Mean   StDev  SE Mean 
HUVEC   3   0.171   0.114    0.066 
+ 25.5 
138 
 
HUVEC   3  0.1642  0.0610    0.035 
+ 10.5 
 
Difference = mu (1) - mu (2) 
Estimate for difference:  0.0065 
95% CI for difference:  (-0.2309, 0.2440) 
T-Test of difference = 0 (vs not =): T-Value = 0.09  P-
Value = 0.936  DF = 3 
 
Two-Sample T-Test and CI  
 
Sample  N    Mean   StDev  SE Mean 
HUVEC   3   0.171   0.114    0.066 
+ 25.5 
HUVEC   3  0.0426  0.0203    0.012 
+ Control 
 
Difference = mu (1) - mu (2) 
Estimate for difference:  0.1281 
95% CI for difference:  (-0.1593, 0.4155) 
T-Test of difference = 0 (vs not =): T-Value = 1.92  P-
Value = 0.195  DF = 2 
 
Two-Sample T-Test and CI  
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Sample  N    Mean   StDev  SE Mean 
DHCAEC  3  0.2191  0.0717    0.041 
+ Control 
DHCAEC  3  0.1609  0.0468    0.027 
+ 10.5 
 
Difference = mu (1) - mu (2) 
Estimate for difference:  0.0582 
95% CI for difference:  (-0.0991, 0.2155) 
T-Test of difference = 0 (vs not =): T-Value = 1.18  P-
Value = 0.324  DF = 3 
 
Two-Sample T-Test and CI  
 
Sample  N    Mean   StDev  SE Mean 
DHCAEC  3  0.2191  0.0717    0.041 
+ Control 
DHCAEC  3   0.319   0.279     0.16 
+ 25.5 
 
Difference = mu (1) - mu (2) 
Estimate for difference:  -0.100 
95% CI for difference:  (-0.815, 0.614) 
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T-Test of difference = 0 (vs not =): T-Value = -0.60  P-
Value = 0.607  DF = 2 
 
Two-Sample T-Test and CI  
 
Sample  N    Mean   StDev  SE Mean 
DHCAEC  3  0.1609  0.0468    0.027 
+ 10.5 
DHCAEC  3   0.319   0.279     0.16 
+25.5 
 
Difference = mu (1) - mu (2) 
Estimate for difference:  -0.159 
95% CI for difference:  (-0.860, 0.543) 
T-Test of difference = 0 (vs not =): T-Value = -0.97  P-
Value = 0.433  DF = 2 
 
RAGE 
Two-Sample T-Test and CI  
 
Sample  N      Mean     StDev  SE Mean 
H + C   3  0.000725  0.000306  0.00018 
H+10.5  3   0.00266   0.00112  0.00065 
 
141 
 
Difference = mu (1) - mu (2) 
Estimate for difference:  -0.001935 
95% CI for difference:  (-0.004831, 0.000961) 
T-Test of difference = 0 (vs not =): T-Value = -2.87  P-
Value = 0.103  DF = 2 
 
Two-Sample T-Test and CI  
 
Sample  N      Mean     StDev  SE Mean 
H + C   3  0.000725  0.000306  0.00018 
H+25.5  3   0.00190   0.00183   0.0011 
 
Difference = mu (1) - mu (2) 
Estimate for difference:  -0.00117 
95% CI for difference:  (-0.00578, 0.00343) 
T-Test of difference = 0 (vs not =): T-Value = -1.10  P-
Value = 0.387  DF = 2 
 
Two-Sample T-Test and CI  
 
Sample  N     Mean    StDev  SE Mean 
H+10.5  3  0.00266  0.00112  0.00065 
H+25.5  3  0.00190  0.00183   0.0011 
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Difference = mu (1) - mu (2) 
Estimate for difference:  0.00076 
95% CI for difference:  (-0.00318, 0.00471) 
T-Test of difference = 0 (vs not =): T-Value = 0.61  P-
Value = 0.582  DF = 3 
 
Two-Sample T-Test and CI  
 
Sample  N       Mean      StDev   SE Mean 
D + C   3  0.0002740  0.0000960  0.000055 
D+10.5  3   0.000909   0.000319   0.00018 
 
Difference = mu (1) - mu (2) 
Estimate for difference:  -0.000635 
95% CI for difference:  (-0.001462, 0.000192) 
T-Test of difference = 0 (vs not =): T-Value = -3.30  P-
Value = 0.081  DF = 2 
 
Two-Sample T-Test and CI  
 
Sample  N       Mean      StDev   SE Mean 
D + C   3  0.0002740  0.0000960  0.000055 
D+25.5  3   0.000753   0.000209   0.00012 
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Difference = mu (1) - mu (2) 
Estimate for difference:  -0.000479 
95% CI for difference:  (-0.001050, 0.000092) 
T-Test of difference = 0 (vs not =): T-Value = -3.61  P-
Value = 0.069  DF = 2 
 
Two-Sample T-Test and CI  
 
Sample  N      Mean     StDev  SE Mean 
D+10.5  3  0.000909  0.000319  0.00018 
D+25.5  3  0.000753  0.000209  0.00012 
 
Difference = mu (1) - mu (2) 
Estimate for difference:  0.000155 
95% CI for difference:  (-0.000545, 0.000856) 
T-Test of difference = 0 (vs not =): T-Value = 0.71  P-
Value = 0.531  DF = 3 
 
eNOS 
Two-Sample T-Test and CI  
 
Sample  N      Mean     StDev  SE Mean 
H + C   3  0.000698  0.000486  0.00028 
H+10.5  3   0.01349   0.00206   0.0012 
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Difference = mu (1) - mu (2) 
Estimate for difference:  -0.01279 
95% CI for difference:  (-0.01806, -0.00753) 
T-Test of difference = 0 (vs not =): T-Value = -10.46  P-
Value = 0.009  DF = 2 
 
Two-Sample T-Test and CI  
 
Sample  N      Mean     StDev  SE Mean 
H + C   3  0.000698  0.000486  0.00028 
H+25.5  3    0.0191    0.0115   0.0066 
 
Difference = mu (1) - mu (2) 
Estimate for difference:  -0.01836 
95% CI for difference:  (-0.04684, 0.01011) 
T-Test of difference = 0 (vs not =): T-Value = -2.77  P-
Value = 0.109  DF = 2 
 
Two-Sample T-Test and CI  
 
Sample  N     Mean    StDev  SE Mean 
H+10.5  3  0.01349  0.00206   0.0012 
H+25.50 3   0.0191   0.0115   0.0066 
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Difference = mu (1) - mu (2) 
Estimate for difference:  -0.00557 
95% CI for difference:  (-0.03448, 0.02334) 
T-Test of difference = 0 (vs not =): T-Value = -0.83  P-
Value = 0.494  DF = 2 
 
Two-Sample T-Test and CI  
 
Sample  N     Mean    StDev  SE Mean 
D + C   3  0.00940  0.00123  0.00071 
D+10.5  3   0.0250   0.0175    0.010 
 
Difference = mu (1) - mu (2) 
Estimate for difference:  -0.0156 
95% CI for difference:  (-0.0592, 0.0281) 
T-Test of difference = 0 (vs not =): T-Value = -1.54  P-
Value = 0.265  DF = 2 
 
Two-Sample T-Test and CI  
 
Sample  N      Mean     StDev  SE Mean 
D + C   3   0.00940   0.00123  0.00071 
D+25.5  3  0.007278  0.000571  0.00033 
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Difference = mu (1) - mu (2) 
Estimate for difference:  0.002127 
95% CI for difference:  (-0.001249, 0.005503) 
T-Test of difference = 0 (vs not =): T-Value = 2.71  P-
Value = 0.113  DF = 2 
 
Two-Sample T-Test and CI  
 
Sample  N      Mean     StDev  SE Mean 
D+10.5  3    0.0250    0.0175    0.010 
D+25.5  3  0.007278  0.000571  0.00033 
 
Difference = mu (1) - mu (2) 
Estimate for difference:  0.0177 
95% CI for difference:  (-0.0259, 0.0613) 
T-Test of difference = 0 (vs not =): T-Value = 1.75  P-
Value = 0.223  DF = 2 
 
147 
 
0.0000100.0000050.000000-0.000005-0.000010
99
90
50
10
1
Residual
P
e
r
c
e
n
t
0.00001500.00001250.00001000.00000750.0000050
0.000005
0.000000
-0.000005
Fitted Value
R
e
s
id
u
a
l
0.
00
00
08
0.
00
00
06
0.
00
00
04
0.
00
00
02
0.
00
00
00
-0
.0
00
00
2
-0
.0
00
00
4
-0
.0
00
00
6
6
4
2
0
Residual
F
r
e
q
u
e
n
c
y
18161412108642
0.000005
0.000000
-0.000005
Observation Order
R
e
s
id
u
a
l
Normal Probability Plot Versus Fits
Histogram Versus Order
ANOVA  Assumptions for Reference Gene Verification
 
